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ABSTRACT
Development of resistance to androgen deprivation therapy (ADT) is a major
obstacle for the management of advanced prostate cancer. Therapies with androgen
receptor (AR) antagonists and androgen withdrawal initially result in tumor regression
but development of compensatory mechanisms including AR bypass signaling leads to
tumor re-growth, independent of circulating androgens. The result is the emergence of
castration resistant prostate cancer (CRPC), a highly morbid disease exhibiting
aberrant expression of many protein-coding and non-coding genes. Under the umbrella
of non-coding RNAs is a class of small regulatory RNAs referred to as microRNAs
(miRNAs). MicroRNAs are believed to function in the maintenance of cell homeostasis
but are often differentially expressed in many different types of cancer including CRPC.
In this study, the association of genome wide miRNA expression (1113 unique
miRNAs) with development of resistance to ADT was determined. Androgen sensitive
prostate cancer cells that progressed to ADT and AR antagonist Casodex (CDX)
resistance upon androgen withdrawal and treatment with CDX were used. Validation of
expression of a subset of 100 miRNAs led to identification of 43 miRNAs that are
significantly altered during progression of cells to treatment resistance. A correlation of
altered expression of 10 proteins targeted by some of these miRNAs in these cells was
shown.
Additionally, profiles of miRNA expressions in cancerous prostate tissues were
created and compared with profiles of paired adjacent uninvolved areas of prostate
iii

tissue. Among the miRNAs identified from these analyses, a cluster of miRNAs, miR17-92a, that is under-expressed in prostate tumors and in androgen independent
prostate cancer cells was highlighted. The miR-17-92a cluster miRNAs are transcribed
from a polycistronic transcription unit C13orf25 that generates six mature miRNAs: miR17, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a, and is commonly de-regulated
in many cancers. In this research, the expression of miR-17-92a miRNAs was found to
be reduced in cancerous prostate tissues when compared to uninvolved areas and also
in aggressive prostate cancer cells. Restoration of expression of all members of miR17-92a cluster showed decreased expression of cell cycle regulatory proteins cyclin D1
and SSH1; as well as LIMK1 and FGD4 of the RhoGTPase signaling pathway.
Expression of miR-17-92a miRNAs caused decreased cell proliferation, reduced
activation of AKT and MAP kinases, delayed tumorigenicity and reduced tumor growth
in animals. Additionally, miR-17-92a miRNA expression inhibited EMT via reduced cell
migration and expression of mesenchymal markers while elevating expression and
surface localization of the epithelial marker e-cadherin. Expression of miR-17-92a
miRNAs improved sensitivity of androgen dependent LNCaP104-S prostate cancer
cells to the Androgen Receptor antagonist bicalutamide (CDX), AKT inhibitor MK-2206
2HCl, and docetaxel. Androgen refractory PC-3 cells also showed increased sensitivity
to docetaxel, MK-2206 2HCl, and Aurora kinase inhibitor VX680 upon ectopic
expression of miR-17-92a cluster miRNAs.
In conclusion, dynamic alterations in miRNA expression occur early on during
iv

androgen deprivation therapy and androgen receptor blockade. The cumulative effect
of these altered miRNA expression profiles is the temporal modulation of multiple
signaling pathways promoting survival and acquisition of resistance. These early events
are driving the transition to castration resistance and cannot be studied in already
developed CRPC cell lines or tissues. Notably, these data demonstrate a tumor
suppressor effect of miR-17-92a cluster miRNAs in prostate cancer cells and
restoration of expression of these miRNAs has a therapeutic benefit for both androgendependent and -independent prostate cancer cells. Furthermore, these results can be
used as a prognostic marker of cancers with a potential to be resistant to ADT.
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CHAPTER ONE: INTRODUCTION
The molecular regulation of gene expression is an extremely complex and multitiered process crucial for the maintenance of normal cellular processes; as such, the
ensuing overview is intended to only provide a framework for understanding the scale
of which this dissertation is investigating.
Gene regulation arbitrarily starts at the level of chromatin structure; here
epigenetic modifications control the accessibility of transcriptional complexes to specific
genetic regions. When chromatin is relaxed, differing patterns of regulatory regions
upstream of genes recruit transcription factors, co-regulator proteins, scaffolding
proteins and RNA polymerases to govern transcription of the gene into RNA. RNAbinding proteins then work to control the stability of transcripts and patterns of splicing,
altering both the concentration of templates available for translation and the complete
sequence of those templates [1]. Translation of mRNAs is further controlled during
initiation, elongation, termination, and recycling of ribosomes [2]. Regulatory RNAs act
at this level to inhibit ribosomal function or direct degradation of the mRNA. Finally,
mature proteins can be modified in many ways which can have a multitude of effects
including: modifying enzyme activity, fine-tuning protein-protein interactions, and
targeting proteins for degradation [3]. The total sum of these processes, and many
additional factors, results in the cumulative regulation of protein functionalities and
concentrations.
The development and progression of cancer is likewise a product of multilayered
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mechanisms spanning time and diverse regulatory events. Unlike the tightly controlled
systems of normal cells, malignancies thrive by hijacking cellular systems and
manipulating these processes to promote growth and survival. Each cancer develops
individually as a result of accumulated cellular insults, mutations, genetic factors, and
extracellular stimuli. Despite the seemingly random series of events promoting the
development of different cancers, the consequence is the convergent evolution of
malignant tissues. Common to all cancers is the deregulation of gene expression
seemingly at every level [4]. Furthermore, aberrant expression encompasses both
protein coding and non-coding genes. This is an essential adaption and functional
consequence that drives the survival and progression of cancer.

1.1 Non-Coding RNAs in Cancer

Non-coding RNAs (ncRNA) are RNA molecules that are not translated into
proteins, and are divided by type. The types include transfer-RNA (tRNA), ribosomal
RNA (rRNA), long non-coding RNA (lncRNA), and microRNA (miRNA) among others.
Non-coding RNAs are involved in many integral cellular processes including but not
limited to RNA splicing, protein synthesis, DNA replication, and regulation of gene
expression [5]. Development of RNA sequencing methods has led to widespread
profiling of many tissue types and disease states. Results of these experiments have
shown that many ncRNAs display altered patterns of expression in cancerous tissues,
and these altered expressions have phenotypic implications [6, 7]. Long non-coding
RNAs and microRNAs are two classes of regulatory RNA molecules and accordingly
2

many members of both classes display strong conservation across species. LncRNAs
and miRNAs act to fine tune the expression of specific genes or genetic loci [8]. Despite
the diverse functions of ncRNAs little was known about these molecules until recently.
This gap in knowledge garnered great interest, and resultant studies have uncovered a
complex interconnected network of differing ncRNAs and proteins which act to regulate
metastatic transformation of cancer (Figure 1).
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Figure 1: Depiction of ncRNA involvement in molecular networks orchestrating cancer
metastasis.
The non-coding (grey boxes) and the protein-coding (white boxes) interactomes co-operate to drive each
step of the metastatic cascade (e.g., tissue invasion, migration, intravasation, and homing in distant
tissues). Different classes of ncRNAs can play partially overlapping functions. A summary of three main
classes includes: 1 Antisense RNA inhibitors, including miRNA-like molecules, competitive endogenous
RNAs (ceRNAs) and ceRNA-antisense transcripts (CATs); 2 epigenetic co-factors; 3 splicing regulators.
Each component of the interactome can activate (arrows) or inhibit (rectangles) other components.
Epigenetic gene regulation is depicted at the border of the two interactomes, since it can control the
expression of both ncRNAs and mRNAs. Moreover, epigenetic effectors are composed of? both proteins
and lncRNAs, piRNA, PIWI interacting RNA, snoRNA and small nuclear RNA.
Source: Crea F, Clermont PL. et al. (2014). “The non-coding transcriptome as a dynamic regulator of
cancer metastasis”. Cancer Metas. Rev., 33(1):1-16. doi: 10.1007/s10555-013-9455-3
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1.1.1 Biogenesis of microRNAs
MicroRNAs belong to a specific class of small regulatory RNAs which was first
discovered in C. elegans. Mature miRNAs, 17–22 nucleotides in length, contain a specific
sequence at their 5’ end which acts to repress translation through binding to the 3’UTR
of the mRNAs [9].The role of small noncoding microRNAs (miRNAs) in regulation of gene
expression, which is mediated by inhibition of translation or degradation of target mRNAs
is an established phenomenon [9]. To date, 1881 distinct human miRNAs have been
identified of which, high confidence displayed in 1357 and, each of which regulate multiple
target mRNAs (www.mirbase.org Jun 2014). Genes encoding miRNAs are located
heterogeneously throughout the genome. Some miRNAs are located distant from protein
coding genes and are driven by their own promoters, while most are located in the introns
of protein coding genes and are regularly co-expressed with the host gene. Moreover,
miRNA genes can be transcribed independently or as part of a polycistronic cluster.
Unique miRNA genes are generally transcribed by RNA polymerase II, producing a
primary miRNA (pri-miRNA) transcript, while miRNA genes cis to ALU repeat regions
have been found to be transcribed by RNA polymerase III [10] [11]. Primary-miRNA
transcripts, which are generally capped at the 5’ terminus, are composed of at least one
stem-loop hairpin, a terminal loop, and a single stranded flanking sequence containing a
polyA-tail [12]. While still located in the nucleus, the flanking sequences of pri-miRNAs
are trimmed into pre-miRNA by the microprocessor complex composed of Drosha and
DGCRG8. For intron encoded miRNAs, splicing of host gene transcripts release the
2

“miRtrons”, producing pre-miRNAs independent of Drosha function [13]. Pre-miRNAs are
then exported from the nucleus by exportin-5 and Ran-GTP. In the cytoplasm the premiRNA hairpin is cleaved by Dicer leaving two mature strands of the miRNA, referred to
as the 5p- and 3p- strands. Although both strands are functional, it is generally accepted
that the strand with the less stable base pairing at the 5′ terminus is preferentially loaded
into the RNA-induced silencing complex (RISC) [14]. In this canonical theory, the miRNA*
or passenger strand, is selected for degradation (Figure 2). Contrary evidence has
emerged from more recent RNA-Seq data which has shown that many miRNA* strands
occur at comparable levels to that of the guide strands. Whereas immunoprecipitation of
Ago proteins has shown a predilection of AGO1/2 for specific 5p- and 3p- strands,
deregulation during cancer may drive strand switching in RISC complexes [15].

3

Figure 2: Biogenesis and functionality of miRNAs
MicroRNAs are transcribed and trimmed into pre-miRNAs in the nucleus before being exported into the
cytoplasm. Next Dicer acts to cleave the hairpin forming the mature miRNAs which are incorporated in
RISC complexes to mediate gene silencing. Source: “miRNA biogenesis: Biological impact in the
development of cancer” [12]
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1.1.2 Mechanisms of miRNA Gene Silencing
The primary function of miRNAs is the translational repression of target mRNAs,
which is achieved through mRNA degradation, translational inhibition, or mRNA decay
through recruitment to P bodies [16, 17]. The mechanism is mediated by which Argonaut
protein binds the miRNA and the degree of complementarity between the miRNA seed
region and the 3’UTR of the mRNA. Ago2 is the principal RISC component involved in
miRNA gene silencing generally through translational inhibition. The cleavage of mRNA
by Ago2 necessitates perfect complementarity of mRNA-miRNA base pairing [18] which
is uncommon in vertebrates. However, this can be achieved through Ago1/3/4 [19, 20].
The extent of gene silencing is also mediated by the number of miRNA binding sites in
the mRNA [21].
The effect of altered miRNA expression can vary widely in significance and
transformative ability. One example in which the modulation of one miRNA can
dramatically shift the gene expression is the overexpression of miR-124 in HeLa cells in
which the protein expression switched to a profile mirroring that found in the brain, a tissue
that expresses high levels of miR-124. Alternatively, when miR-1 is overexpressed, a
miRNA highly expressed in muscle tissue, the cells express mRNA profiles consistent
with that of muscle cells [22].
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1.2 Prostate Cancer

1.2.1 Epidemiology of Prostate Cancer
Prostate cancer is the second most prevalent malignancy in American men,
ranking just behind skin cancer. The American Cancer Society estimates that in 2016
180,890 new cases of prostate cancer will be diagnosed with an unfortunate 26,120
patients succumbing to the disease (ACS March 2016). This places prostate cancer as
the second leading cause of cancer deaths in American men, behind only lung cancer.
Prostate cancer normally develops in men over the age of 60 and rarely forms before age
40. Despite the fact that 1 in 7 men will develop prostate cancer in their lifetime, on
average only 1 in 39 American men will die from prostate cancer. This discrepancy is a
result of several factors including medical intervention, slow growth and confinement to
the prostate in many cases, and later onset in age, leaving many men to die from other
causes. There are risk factors which aggravate this scenario including family history, diet
and obesity, STDs, and inflammation and sex hormone levels [23]. Furthermore, race and
socioeconomic status are key factors contributing to the development and mortality rates
of prostate cancer. African American and Caribbean men of African ancestry have the
highest incidences of prostate cancer followed by Caucasians, Hispanics, and Asian men.
Higher risk of prostate cancer is further linked with lower socioeconomic status [24].
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Most prostate lesions develop in the form of benign prostatic hyperplasia (BPH) or
prostatic intraepithelial neoplasia (PIN). BPH is largely not considered as a precursor of
cancer in the prostate [25]. This is because BPH normally occurs in the transitional zone
encompassing both epithelial and stromal tissues [26] [27]. The anatomy of the prostate
and location of zones is displayed in Figure 3. High grade PIN, in contrast to BPH, is
believed to be a precancerous condition. PIN is characterized by abnormalities of
epithelial cells lining the glands and ducts in the prostate while basal cell architecture
remains present. Prostate cancer more commonly develops from abnormal epithelial cells
in the peripheral zone.

Figure 3: Anatomy of the prostate gland
The prostate gland is located below the bladder and surrounds the urethra. BPH is a common abnormality
of the transitional zone (Green) while malignant lesions normally develop in the peripheral zone (Purple).
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The Gleason scoring system is used to judge the progression of the tumor, early on
when the tumor tissue is still well differentiated and retains many small glandular
structures. As the cancer progresses, the tissue becomes less differentiated and basal
cells are lost as the lesion infiltrates the surrounding stroma. Well differentiated tissue
structure is assigned low values while poorly differentiated tissue structure is assigned
high Gleason scores (Figure 4).

Figure 4: Gleason scoring system classification
Depiction of prostate tissue architecture in association with Gleason score.
Source: NIH SEER training modules
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1.2.2 Androgen Receptor and Importance of Androgen Signaling
The Androgen Receptor (AR) is a nuclear receptor activated by androgens, a class
of steroid hormones which includes 5α-dihydrotestosterone (DHT) the primary ligand of
AR. In the absence of androgens, AR is primarily localized to the cytoplasm and is bound
by HSPs-90/-70 where it is indirectly tethered to cytoskeletal proteins. Upon ligand
binding, the heat shock proteins dissociate and AR is translocated to the nucleus. Active
ARs dimerize and interact with co-regulators to drive the transcription of genes with
androgen response elements in their promoter.
During prostate development the activation of AR, results in the elevated
expression of transcription factors, and growth factors in prostate progenitor cells. The
net effect is the increased activity of signaling pathways which promote survival,
proliferation, and invasion. This drives the formation and remodeling of the immature
prostate. In the adult prostate, androgen signaling is necessary for maintaining the
proliferation and secretory function of luminal epithelial cells.
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1.2.3 Therapeutic Strategies
Treatment options for prostate cancer depend on several basic criteria: 1) tumor
stage and likelihood of progression, 2) localized or metastatic disease, and 3) risk/reward
to patient. In the past, “watchful waiting” (WW), a palliative observational strategy, was
commonly prescribed for patients diagnosed with low risk clinically localized prostate
cancer. This was recommended because of the slow progression common in prostate
cancer combined with the increased risk of surgery or radiation for elderly patients.
However as of late, this strategy has come under criticism and is being replaced by “active
surveillance” (AS) which is undertaken with a similar mindset but involves regular biopsies
and testing for PSA levels. If the oncologist determines that immediate intervention is
necessary, several options exist which are listed in Table 1.
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Table 1: Therapeutic options for the management of prostate cancer

Treatment
Watchful waiting

Description
A palliative observational strategy that consists of intervening
only when symptoms appear

Active surveillance

A strategy with curative intent that involves regular monitoring
of PSA levels and repeat biopsies

Radiation therapy

Conventional external beam radiation therapy (EBRT)
•Three-dimensional conformal radiation therapy (3D-CRT)
•Intensity-modulated radiation therapy (IMRT)
•Proton beam radiation therapy (PBRT)
•Stereotactic body radiation therapy (SBRT)

Interstitial

A strategy whereby tumor tissue is specifically targeted by

brachytherapy

placing seeded radioactive material in or near the tumor

Radical

Open perineal

prostatectomy

•Open retropubic
•Laparoscopic
•Robotic-assisted laparoscopic

Cryotherapy

A strategy that uses very low temperatures to freeze and kill
the tumor cells in the prostate

High-intensity

A procedure that applies high-intensity focused ultrasound

focused

energy to locally heat and destroy tumor tissue

ultrasound (HIFU)
Source: Mottet N, et al. Guidelines on Prostate Cancer. Euro. Assoc. of Urology 2015
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1.2.4 Androgen Independence
Androgen signaling drives the development and progression of prostate cancer.
For this reason, androgen blockade is commonly used in therapeutic strategies for
patients diagnosed with disseminated or locally confined advanced prostate cancer.
While androgen deprivation therapy can induce significant tumor regression, the efficacy
is transient. Ultimately, the treatment fails and the disease progresses to a highly
malignant form referred to as androgen independent or castration resistant prostate
cancer.
The development of androgen independent prostate cancer (AIPC) has been
studied extensively and has revealed a diverse range of adaptive mechanisms employed
by surviving tumor cells. It is generally accepted that the tumor cells initially adapt to the
low androgen environment by becoming androgen hypersensitive. Through ramping up
the expression of AR and its co-regulators, the cells are able to maintain basal levels of
AR signaling in androgen depressed conditions. Furthermore, over active growth factor
signaling pathways and expression of alternative AR isoforms or mutants can lead to
ligand independent activity of AR. In the long-term androgen independent cells exhibit
commonalities characterized by altered protein expression. The exact expression profiles
vary between tumors, and AIPC cell lines alike, but show a trend toward increased
expression and activity of proteins promoting proliferation and survival and decreased
repressors of such. (↑ EGFR [28], ↑ IGFR[29], ↑ Cdks/Cylins [30], ↑ FOXA1 [31], ↓ PTEN
12

[32], ↓ p21 [33], etc), as well as the overhaul of metabolic pathways [34], especially those
involved steroid signaling and synthesis [35, 36]. Paracrine and autocrine androgen
biosynthesis is known to occur in the cells of tumor microenvironment and in the prostate
cancer cells thus providing sufficient androgen levels to circumvent ADT [37, 38]. The
rewiring of molecular networks observed in androgen independent prostate cancer is both
an origin and a consequence of alterations in gene expression; the evolution of which is
still subject to the regulatory mechanisms and molecules described earlier, including noncoding RNAs.
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1.3 MicroRNAs in Cancer

1.3.1 Involvement of miRNAs in carcinogenesis
Many diseases, including cancer, are associated with abnormal transcriptomes.
This dysregulation of RNA expression encompasses both protein-coding and non-coding
RNAs. MicroRNAs have been found to be aberrantly expressed during the development
and progression of a wide spectrum of different cancers [39, 40]. Simplistically, this leads
to increased concentrations of oncogenic miRNAs with a corresponding decrease in
tumor suppressive miRNAs, often from the duplication or deletion of genetic regions. In
reality the oncogenic or suppressive function of a miRNA is cell type specific and
mediated by the landscape of mRNAs, pseudogenes, and competitive RNAs (ceRNAs),
amongst other factors [41, 42]. MicroRNA effectors may change between cancer types;
however, the effects are similar: drive proliferation, inhibit apoptotic initiation, and promote
a stem-like & invasive phenotype. The miR-106a-363 cluster, commonly up-regulated in
cancer, targets PTEN promoting PI3K-AKT signaling and proliferation and survival [43].
Conversely, the down-regulation of the let-7 and miR-200 families, can induce epithelial
to mesenchymal transition (EMT) and increase invasiveness in PCa cells [44, 45]. A
summary of miRNAs altered in prostate cancer and the pathways affected is listed in
Table 2.
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Table 2: List of miRNAs altered in prostate cancer and the mRNA targets
MiRNA

Expressi
on

miR-21

mRNA target

Pathway

Up

PTEN, AKT, androgen pathway

Apoptosis, mTOR pathway, A.I.

miR-24

Up

FAF1

Apoptosis

miR-32
miR106b
miR125b
miR148a

Up

BCL2L11(Bim)

Apoptosis

Up

P21, E2F1

Cell Cycle/Apoptosis and Proliferation

Up

P53, BBC3(Puma), BAK1

Apoptosis

Up

CAND1

Cell Cycle

miR-221

Up

p27(kip1)

Cell Cycle and A.I.

miR-222

Up

p27(kip1)

Cell Cycle and A.I.

miR-521

Up

Cockayne syndrome protein A

DNA Repair

miR-1

Down

Exportin-6, tyrosine kinase 9

Gene Expression

miR-7
miR-15a16

Down

ERBB-2 (EGFR, HER2)

Down

CCND1 and WNT3a

Signal Transduction
Cell Cycle Regulation, Apoptosis and
Proliferation

miR-34a

Down

HuR/Bcl2/SIRT1->p53/p21/BBC3

Apoptosis and Drug-Resistance

miR-34c

Down

E2F3, bcl2, MET

Apoptosis and Proliferation

miR-107

Down

Granulin

Proliferation

miR-143

Down

Migration, Proliferation

miR-145
miR148a

Down

MYO6, ERK5
MYO6, BNIP3L->AIFM1, CCNA2,
TNFSF10

Down

MSK1

Migration, Apoptosis, Cell Cycle
Proliferation, stress response and drug
resistance

miR-205
miR-3313P
miR1296

Down

IL-24 and IL-32, Cepsilon

Cell Growth and Invasion, EMT

Down

ERBB-2, CDCA5, KIF23

Signal Transduction, Cell Cycle

Down

MCM family

DNA Replication

Let-7a

Down

E2F2 and CCND2

Cell Cycle and Proliferation

A.I. androgen independence
Source: Catto et al. 2011. MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review.
doi:10.1016/j.eururo.2011.01.044
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1.3.2 Association of miRNAs with CRPC
Castration resistant prostate cancer is a highly morbid disease and by definition is
unresponsive to androgen deprivation. In spite of this clinical consequence, androgen
independent cells commonly exhibit a highly active androgen receptor signaling axis
important for growth and survival. The androgen receptor is known to modulate the
expression of over 100 miRNAs. In prostate cancer, 22 miRNAs are well documented
[46]. Sixteen miRNAs are induced by DHT (miR-594, -16, -21, -29a/b/c, -148a, -106a, 17–5p, -20a, -20b, -19b, -93, -15b, let-7g, and let-7d), and display altered expression in
PCa [47]. Alternatively, miR-340, -222, -16, -100 -126*, -23b, -133a-1, and -499 are
down-regulated by AR activity and show reduced expression in PCa [48]. MicroRNAs are
also involved in the regulation of AR expression and activity, including miR-541, -34c, 299, -135b which directly target the 3’ UTR of AR mRNA [49]. Additionally, miR-17 can
inhibit the expression of P300/CBP, a co-activator of AR, and FOXA1 which modulates
AR activity [50, 51].
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CHAPTER TWO: HYPOTHESIS AND SPECIFIC AIMS
MicroRNAs (miRNA) are recognized as a group of small noncoding RNAs that play
a variety of roles in the regulation of biological processes mainly through repression of
gene expression at the translational level. MicroRNAs have a unique expression profile
that varies in a tissue and disease specific manner [52],[53]. Expression of miRNAs is
often deregulated early in cancer progression, which facilitates development of
aggressive and drug resistant disease [54, 55]. However, the progressive modulation of
miRNA expressions has not been identified during the acquisition of resistance to antiandrogen therapy in vitro; moreover, a correlative analysis of miRNA expression profiles
with a patient’s risk of biochemical failure, which could provide a significant prognostic
tool for clinicians, has never been done. We hypothesize that differential expression of
miRNAs are associated with the progression of prostate cancer and with the development
of androgen independence and anti-androgen (AA) drug resistance.
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2.1 Aim #1. Identify miRNAs, and their protein targets, with altered expression during
development of androgen independence

In this aim we will profile the expressions of 1113 miRNAs in prostate cancer cells
subjected to androgen ablation and AA drug treatment and identify miRNAs displaying
statistically significant changes. Using prediction algorithms, we will identify putative
target genes and determine if expression of the genes was effected.

2.2 Aim #2. Identify miRNA(s) differentially expressed in tumor tissues and investigate
the role the miRNA(s) play in prostate cancer development

In this aim we will profile miRNA expressions in clinical tissue, and identify
deregulated miRNAs. MicroRNAs commonly deregulated in patient tumors and in
androgen independent prostate cancer cells will be chosen for further investigation.
Expression of these miRNAs will be manipulated in prostate cancer cells and phenotypic
changes will be observed.
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2.3 Aim #3. Screen and correlate expression of miRNAs in clinical specimens with
different predictive outcomes

In this aim we will profile miRNA expressions from additional patient tumors. These
miRNA profiles will then be correlated with the patient’s risk of biochemical recurrence
following surgery, identified from the patient’s pathological chart information.
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CHAPTER THREE: MATERIAL AND METHODS:
3.1 Cell Culture and Androgen Deprivation

LNCaP sublines LNCaP-104S and LNCaP-104R1 were a gift from Dr. Shutsung
Liao (University of Chicago). LNCaP-104S cells, androgen dependent, were passaged in
DMEM (Life Technologies) containing 10% Fetal Bovine Serum (Atlanta Biologicals) and
1% antibiotic/antimycotic (Life Technologies) at 37°C, 5% CO2. LNCaP-104R1 cells,
androgen independent, were maintained in DMEM containing 10% Charcoal-stripped
Fetal Bovine Serum and 1% antibiotic/antimycotic (Life Technologies) at 37°C, 5% CO2.
Charcoal stripped FBS was prepared by incubating FBS with dextran(T-70) coated
activated charcoal, at 45˚C for 1hr while stirring. Dextran coated charcoal was separated
from serum by two rounds of centrifugation (3,000 rpm, 5 min). Serum was transferred to
new conical tubes and stored at -20˚C. Because LNCaP cells do not reach 100%
confluence, cells were subcultured on every second to third day. Cell dissociation process
is as detailed, first, monolayer was washed with DPBS, then DPBS containing 0.05%
trypsin-EDTA solution (Life Technologies) was added to culture dish for 30 seconds at
room temperature. Next, trypsin-EDTA solution was aspirated and the culture dish was
placed in 37°C incubator for 3 to 5 minutes. The dissociated cells were then suspended
in complete growth media and split (1:3). Because LNCaP cells adhere relatively loosely
to culture surfaces, caution was exercised when pipetting DPBS or media into culture
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vessels containing attached cells.
The isolation of LNCaP-104S cells resistant to androgen deprivation was
conducted as follows. LNCaP-104S cells were maintained in DMEM containing 10%
Charcoal-Stripped Fetal Bovine Serum (CS-FBS), supplemented with or without 5 µM
Casodex (Fluka). Samples of treated cells were harvested at 7, 14, and 21 days.
Harvested cells were used for either RNA extraction or protein extraction. Treated cells
were compared to untreated samples collected before treatment. To start treatment,
1x106 LNCaP-104S cells were seeded in 100mm tissue culture dishes in DMEM
containing CS-FBS and allowed to adhere for 24 hours. The media was then carefully
aspirated and changed to fresh CS-FBS media, containing 10% conditioned media and
supplemented with or without 5 µM Casodex (CDX). Cells were passaged every two days.
Following the first week of treatment, cell proliferation had been suppressed, and during
the second week of treatment many cells had undergone apoptosis. At this point, the
surviving cells were dissociated and seeded at 1x106 cells per 100mm dish every fourth
day, to maintain sufficient cell density. Media was changed in between subculturing.
During the third week of treatment, cells maintained in CS-FBS media started to recover
and proliferate in a more uniform fashion, compared to cells maintained in CDX where
proliferating cell populations were limited to clonal clusters. Following 21 days of
treatment, all viable cells were harvested from both CS-FBS and CDX treated dishes.
PC-3 cells (ATCC) were maintained in F-12 Kaighn’s Modification HAM (Sigma)
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10% Fetal Bovine Serum (Atlanta Biologicals) and 1%

antibiotic/antimycotic (Life Technologies) at 37°C, 5% CO2. When cells reached roughly
80% confluence, the monolayer was dissociated using trypsin-EDTA solution (Life
Technologies). Dissociation process is as detailed, first monolayer was washed with
DPBS, then DPBS containing 0.05% trypsin-EDTA solution was added to culture dish for
3 minutes at room temperature. Next, trypsin-EDTA solution was aspirated and the
culture dish was placed in 37°C incubator for 3 to 5 minutes. The dissociated cells were
then suspended in complete growth media and split (1:3) in complete media.
M12 cells, a metastatic subline derived from SV-40 large T antigen immortalized
human prostate epithelial cells (P69), were obtained as a gift from Dr. Joy Ware (Medical
College of Virginia). M12 cells were maintained in RPMI-1640 (Sigma Aldrich)
containing Insulin 5μg/mL, Transferrin 5μg/mL, Selenium 5ng/mL (BD Biosciences),
dexamethasone (100 nM) (Sigma), EGF (10ng/mL) (BD Biosciences), and gentamicin
(0.05 mg/mL) (Life Technologies). Cells were passaged at 70-80% confluence.
Dissociation process is as detailed, first monolayer was washed with DPBS, then DPBS
containing 0.05% trypsin-EDTA solution was added to culture dish for 5 minutes at room
temperature. Next, trypsin-EDTA solution was aspirated and the culture dish was placed
in 37°C incubator for 5-10 minutes. The dissociated cells were then suspended in
complete growth media and split (1:5) in complete media supplemented with 5% fetal
bovine serum. After cells were attached, media was changed to serum free complete
media.
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3.2 Patient Selection and Procurement of Human Prostate Tissues

Prostate tissues obtained by radical prostatectomies were procured in the
Cooperative Human Tissue Network (Southern division) at the University of Alabama at
Birmingham (UAB) in accordance with an approved IRB protocol. Following surgery,
prostate tissues were formalin-fixed and paraffin embedded (FFPE). Tissues were later
analyzed by a pathologist, macro-dissected and re-embedded in paraffin. Twenty micron
sections were cut from paraffin blocks and collected as curls in RNase-free microcentrifuge tubes.
Patients were selected based on their CAPRA-S score, a prognostic tool for
predicting a patient’s risk of biochemical failure following radical prostatectomy. The
criteria used to derive CAPRA-S scores is detailed in Table 3. The association of CAPRAS score with a patient’s probability of progression free survival is listed in Table 4. To
classify patients, we designated scores 0-2 as low risk, scores 3-5 as medium risk, and
scores ≥6 as high risk [56]. Applying this classification system, we obtained paired
samples from 8 patients in each risk group, tumor tissue and matched uninvolved
adjacent prostate tissue. The samples were stored at -80˚C until RNA was extracted.
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Table 3: CAPRA-S Scoring Criteria

Source: Cooperberg MR, et al. The CAPRA-S score: A straightforward tool for improved prediction of
outcomes after radical prostatectomy. Cancer. 2011 Nov 15;117(22):5039-46. doi: 10.1002/cncr.26169.
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Table 4: Projected Patient Outcomes

Source: Cooperberg MR, et al. The CAPRA-S score: A straightforward tool for improved prediction of
outcomes after radical prostatectomy. Cancer. 2011 Nov 15;117(22):5039-46. doi: 10.1002/cncr.26169.
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3.3 RNA Extraction and cDNA Synthesis

RNA extraction from culture cells: RNA was extracted from cultured cells using the
Cells-to-Cts kit from System Biosciences and processed as follows. Cultured cells were
dissociated as previously described, suspended in ice cold DPBS, pelleted by
centrifugation at 1,250 rpm at 4˚C for 5 minutes. Cell pellets were suspended in ice cold
DPBS and counted using a hemocytometer. Cells (1x106) were then transferred to a new
conical tube, pelleted, suspended in cold DPBS again, and transferred to a
microcentrifuge tube. Cells were pelleted at 3,000 rpm for 5 mins. Cell pellets were finally
suspended in 100 µL of ice cold Cells-to-Cts buffer, and incubated for 10 minutes at 75˚C.
Samples were cooled on ice and 2 µL of DNase I was added to cell lysates, followed by
a 15-minute incubation at 37˚C. Next, the added DNase was inactivated by incubating the
samples at 75˚C for 5 minutes. Lysates were quickly cooled on ice, then stored at -80 ˚C
or immediately used for cDNA synthesis.
RNA extraction from clinical specimens: RNA extraction from FFPE tissue sections
(curls) was conducted using the RecoverAll kit from Life Technologies. RNA was isolated
from 80 µm thick sections (four 20 µm curls) from tissue blocks prepared from macrodissected FFPE tissue. First, paraffin was removed from sections by adding 100% xylene
to curls placed in RNase free micro-centrifuge tubes incubated at 50˚C for 3 minutes.
Next, samples were centrifuged for 2 minutes at 13,000 × g and xylene was discarded.
Tissues were washed twice with 100% ethanol and allowed to air dry. Tissues were then
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digested with protease and incubated at 50˚C (15 min) and 80˚C (15 min). The isolation
additive/ethanol solution was added to lysates and this mixture was passed through the
filter cartridge (10,000 × g for 30 s). The filter cartridge was washed once with Wash 1
and twice with Wash 2/3 solutions. DNase was added directly to the filter and the filter
cartridge was incubated at room temperature for 30 minutes. The filter cartridge was then
washed with Wash 1 and twice with Wash 2/3 to remove degraded DNA. Total RNA was
eluted by adding 50 µL of Elution Solution directly to the filter, and incubating the filter
cartridge at room temperature for 1 min. Eluted RNA was collected by centrifugation
(10,000 × g for 1 min).
Synthesis of cDNA was conducted using the QuantiMir RT kit from System
Biosciences. For total RNA extracted using the Cells-to-Cts kit, 5 µL of Cells-to-Cts cell
lysate was directly used for cDNA synthesis. Alternatively, 100 ng of total RNA extracted
using the RecoverAll kit was used for each cDNA synthesis reaction. For both RNA
extracts, poly-A tail synthesis was first conducted by combining 5 µL RNA, 2 µL 5x PolyA
Buffer, 1 µL 25mM MnCl2, 1.5 µL 5mM ATP, and 0.5 µL PolyA polymerase in a PCR tube
then incubating at 37 ˚C for 30 min. Following polyadenylation of the RNAs the oligo dT
anchor was annealed to the RNAs as follows: 0.5 µL Oligo dT adapter was added to the
RNAs, and incubated at 60˚C for 5 min, then cooled to room temperature for 2 min. Final
reverse transcription was accomplished at 42˚C for 60 minutes, followed by inactivation
of reverse transcriptase at 95˚C for 10 minutes. QuantiMiR cDNAs were then stored at 20˚C.
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3.4 Quantitative Real-Time PCR

Expression of mature microRNAs from both cultured cells and FFPE tissues was
determined by quantitative real-time PCR (qRT-PCR) using the miRNome microRNA
Profiling Kit (System Biosciences). The kit provides specific primers for 1,113 mature
miRNAs and includes primers for 3 internal control RNAs (U6 snRNA, RNU43 snoRNA,
RNU1A snRNA). MicroRNA IDs listed in the text are based on Sanger miRBase
identifiers. Primers were designed to maintain uniform amplification efficiencies. qRTPCR reaction mixtures were prepared using 2x Maxima SYBR Green/ROX qPCR Master
Mix (Thermo-Fisher). The following conditions were used qPCR cycling: Stage 1: 50˚C
for 2 min (1 cycle), Stage 2: 95˚C for 10 min (1 cycle), Stage 3: 95˚C for 15 sec, 60˚C for
1 min (40 two-temperature cycles). For genome wide profiling, 384-well plate (ABI) format
containing 6 µL reaction volume was used for each well. For validation runs, a larger scale
reaction volume, 15 µL, was used per well in a 96-well (ABI) plate format. qRT-PCR was
conducted using the Applied Biosystems Inc. 7900HT thermal cycler equipped with 384well plate module. The data was initially analyzed using the SDS 2.3 software (ABI). DNA
concentrations were reported through SYBR Green fluorescence and normalized to that
of the passive reference dye, ROX. Ct values calculated by the SDS 2.3 software were
transferred to the miRNome analysis software (SBI) to derive ΔΔCt values. The miRNome
analysis calculates the ΔCt values based of the mean of the reference genes. The
individual ΔCt values are then compared across samples to generate the ΔΔCt values for
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each miRNA. miRNAs that showed significant changes in expression were then subject
to further analysis. The statistical analysis of the qRT-PCR data is described in detail in
the follow paragraphs.
Normalization of qRT-PCR expression values was further refined using the
qBasePlus software (Biogazelle). Using the Genorm functionality included with the
qBasePlus software, 7 additional stably expressed miRNAs were identified. The ΔCt
value for each miRNA was then re-calculated utilizing the 7 additional miRNAs plus the 3
original controls. Following normalization, the expression of the reference miRNAs was
re-evaluated to ensure their stability across samples was maintained.
Fold change values were calculated next to determine the relative changes in
miRNA expression as treatment of LNCaP-104S cells progressed to CDX resistance or
to determine expression differences between paired uninvolved and tumor tissues. These
values were generated using the qBasePlus software. After normalization, the software
assigned relative expression values where mean expression of the reference genes is
determined to be a value of 1. Expression of each miRNA is then assigned a relative
expression value in respect to the geometric mean of the controls. The geometric means
were compared using the formula: ∆Ct control= 2-(GMc-GMr)
Where GMc is the geo-mean of the control sample and GMr is the geo-mean of the
reference sample. The fold change, or ∆∆Ct, for each miRNA was then calculated using
the formula: ∆∆Ct= 2-(CtR-CtC)*(∆Ct control)
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Where CtR= Reference sample miRNA Ct value, and CtC= Control sample miRNA Ct
value.
Z-scores were calculated to rank miRNAs for use in selecting candidates for further
investigation. This was accomplished by, first determining the ΔΔCt (Ai) of all miRNAs and
using these values to derive the Global mean (g).
𝑛𝑛

𝑛𝑛
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The global mean is then used to determine the global standard deviation for each
comparison using the formula

∑𝑛𝑛𝑖𝑖=1(𝑙𝑙𝑙𝑙𝑨𝑨𝑖𝑖 − 𝑙𝑙𝑙𝑙𝒈𝒈))2
�
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From which z-scores were determined using the formula.

𝑧𝑧 =

𝐴𝐴 − 𝑔𝑔
𝜎𝜎

Additional analysis was conducted using Cluster 3.0 and heat maps were
generated by Java TreeView softwares. Multiexperiment Viewer software (MEV) was
used for K-means clustering, T-tests, and volcano plots.
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3.5 Plasmid DNA Purification and Transfection

DNA plasmids were purchased from their respective supplier and transformed into
XL-10 Gold ultra-competent cells (Stratagene). Glycerol stocks of the transformed
bacterial cells were prepared and stored at -80˚C. To purify the plasmids, liquid cultures
were first prepared using 3mL L/B broth, appropriate antibiotic (10 mg/mL ampicillin or 30
mg/mL kanamycin), and 20 µL of the glycerol stock. The liquid cultures were grown at for
16 hours at 37˚C while shaking at 250 rpm. The cultures were pelleted into
microcentrifuge tubes and resuspended in 600 µL TE buffer. The purification of all the
plasmids was conducted using the Pureyield Plasmid Miniprep System (Promega). The
cells were lysed by adding 100 µL of Cell Lysis Buffer to the 600 µL bacterial suspensions.
Tubes were inverted six times to ensure even mixture. The lysis buffer was then
neutralized with 350 µL of Neutralization Solution, and centrifuged at maximum speed for
4 minutes. The supernatant was transferred to a new PureYield Minicolumn and
centrifuged at 10,000 x g for 60 seconds. The flow through was disposed of and 250 µL
of Endotoxin Removal solution was added to the column and centrifuged at 10,000 x g
for 60 seconds. The column was then washed with 500 µL Column Wash solution, and
centrifuged at 10,000 x g for 60 seconds. The plasmid DNA was then eluted using 40 µL
of sterile TE buffer, and centrifuged at 10,000 x g for 60 seconds. Quality and
concentration of

the purified DNA was
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then assessed using a NanoDrop

spectrophotometer, additionally agarose gel electrophoresis was used to determine
plasmid size and degree of supercoiling. The purified plasmids were then stored at 4˚C.
The transfection of DNA plasmids was carried out using Lipofectamine 3000 transfection
reagents (Life Technologies). The DNA was first diluted in OptiMem, followed by addition
of the P3000 reagent. This solution was mixed and incubated for 2 minutes, during this
time the Lipofectamine 3000 reagent was diluted into OptiMem in a separate tube. The
diluted Lipofectamine 3000 solution was then added to the diluted DNA solution, mixed
and incubated for 10 minutes at room temperature. The ratios of DNA to Lipofectamine
3000 is cell line specific. Listed in Table 5 are the cell lines specific mixtures used to
transfect an individual well of a 6-well plate, containing 2 mL of complete media.
Table 5: Cell line specific transfection protocol

Cell Line
PC-3

DNA/P3000 Mix

Lipofectamine Mix

125 µL OptiMem

125 µL OptiMem

1.25 µg DNA

3.7 µL Lipofectamine 3000

2.5 µL P3000
LNCaP

125 µL OptiMem

125 µL OptiMem

2 µg DNA

5.5 µL Lipofectamine 3000

4 µL P3000
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3.6 Whole Cell Protein Extraction and Immuno-Blotting

Cells were harvested by trypsinization, washed twice with ice cold DPBS. Cell
pellets were thoroughly resuspended in ice cold passive lysis buffer (5mM Tris, pH 7.5,
2mM EDTA, 150mM NaCl, 1% Nonidet P- 40, 0.1% sodium deoxycholate, 5% glycerol)
containing Halt Protease and Phosphatase Inhibitors Cocktail (Thermo-Fisher). The
samples were placed on ice for 10 minutes, with vortexing for 20 secs at 5 and 10 minutes.
The samples were then subjected to one round of freeze thawing. This was executed by
flash freezing in liquid nitrogen then quickly thawing in a 37˚C water bath, and vortexing
for 15 secs before placing the samples back on ice for 5 minutes. The insoluble fraction
was then separated by centrifugation at 13,000 x g for 15 minutes at 4˚C. The soluble
fraction was then transferred to a new tube, and the protein concentration was determined
by Bradford assay. Samples were then prepared to be separated by SDS-PAGE. The
samples consisted of 50 µg extracted protein diluted in Laemmli sample buffer (to a final
concentration of 33mM Tris-HCl pH 6.8, 10% glycerol, 1% SDS, 355 mM bmercaptoethanol, 0.01% bromophenol blue). Samples were separated on 10% or 12%
SDS-PAGE gels, and transferred to PVDF membranes (Pall) using a wet transfer system
(Bio-Rad). Membranes were transferred to trays and rocked in India ink diluted 1:1000 in
TBS-T (20mM Tris base, 137mM NaCl, 0.1% Tween, pH 7.6) to stain the transferred
protein bands. The membranes were then blocked for 90 minutes using 5% milk in TBS33

T or 2% BSA in TBS-T. Primary antibodies were diluted in the corresponding blocking
solution and applied to the membranes using a SURF blotter (Idea Scientific), which has
channels that align with the sample lanes. Membranes were incubated with primary
antibodies while rocking overnight at 4˚C or for 1-3 hours at room temperature. Nonspecific antibodies were removed from the membranes by rocking the membranes in
blocking solution for 5 minutes per wash, 4 wash cycles. Membranes were then incubated
with HRP conjugated secondary antibodies diluted in 5% milk in TBS-T. Nonspecific
antibodies were removed through 4-6 15 min washes with TBS-T. Immun-Star WesternC
kit (Biorad) chemiluminescent substrate solution was added to the membranes and
antibody staining was visualized and quantified using ChemiDoc XRS imaging system
paired with Image Lab software (Bio-Rad). Using the intensity quantification function of
the Image Lab software, intensity values for individual bands were generated. Antibody
of interest band values were normalized to the paired values from the loading control
antibodies. These normalized values were then used to compare across samples.
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Table 6: Dilutions of antibodies and incubation times

Target
Antigen

Supplier

FGD4
ABHD3
AR
PSA
Cbl
TRAF6

Genetex
Biorbyt
US Biological
Santa Cruz
Santa Cruz
Millipore

ZFAND1
Santa Cruz
IRAK1
Santa Cruz
DOK4
Santa Cruz
VEGF
Santa Cruz
EGFR
Santa Cruz
ERK1/2
Cell Signaling
(pT202/pY204
PRAS40
Cell Signaling
p-PRAS40
Cell Signaling
Cyclin D1
Neomarker
3
Cofilin(pS )
Cell Signaling
LIMK1
BD
p27
Santa Cruz
AKT (pS473)
Cell Signaling
AKT
Transduction Labs
ERK1/2
Cell Signaling
E-Cadherin
Cell Signaling
Slug
Cell Signaling
Vimentin
Cell Signaling
TWIST1
Gentex
TCF8/ZEB1
Cell Signaling
N-Cadherin
Cell Signaling
SSH-1
Cell Signaling
GAPDH
Sigma
α-tubulin
Sigma
γ-tubulin

Sigma

Product
No.

Host

Dilution
Factor

Incubation
Condition

Rabbit
Rabbit
Mouse
Goat
Rabbit
Rabbit

1:350
1:100
1:800
1:350
1:300
1:250

o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C

Rabbit
Mouse
Rabbi
Goat
Goat
Rabbit

1:100
1:250
1:150
1:400
1:500
1:800

o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C

1:800
1:800
1:100
1:100
1:100
1:100
1:350
1:1000
1:600
1:700
1:150
1:200
1:150
1:100
1:300
1:1000
1:1000
1:1000

o/n; 4°C

3396
13116
13578
G8795
T9206

Rabbit
Rabbit
Mouse
Rabbit
Mouse
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Mouse
Mouse

T3559

Rabbit

1:500

1hr; RT

GTX109859

orb31915
030771
sc-7638
sc-170
061110
sc-87505
sc-5288
sc-130133

sc-152
sc-03-G
4370
2691
13175
MS-210P1
3313
611748
sc-528
4060
N/A
4695
3195
9585
5741
GTX60776
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o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
o/n; 4°C
1hr; RT
1hr; RT

Table 7: Immunoblotting Secondary Antibodies

Target
Antigen
Rabbit
IgG
Mouse
IgG
Rat IgG

Supplier
Jackson
Labs
Jackson
Labs
Jackson
Labs

Product
No.
111-035003
115-035003
112-035003

Host
Goat

Diluion
Factor
1:5000

Incubation
Condition
1hr; RT

Goat

1:10000

1hr; RT

Goat

1:10000

1hr; RT

3.7 MTS Colorimetric Assay

The MTS assay (Promega) relies on the active conversion of soluble tetrazolium
into insoluble reduced salts. With this conversion by NADPH reductase, the solution
changes from a pale yellow color to red-brown, with a strong absorbance at 490 nm
wavelength. Monitoring the changes in absorption at 490 nm allows for the relative
quantification of viable cells in each sample well. Cells were passaged the day prior to
seeding of 96-well assay plates, to ensure cell populations were in the log-phase of
growth. Cells were dissociated with a trypsin-EDTA solution, washed in DPBS and
counted using a hemocytometer. The appropriate number of cells were then transferred
to a new conical tube containing enough complete media needed to fill the number of
desired wells. The cell suspension was then equally divided into a pipetting basin. Equal
volumes of the cell suspension were then distributed to each well using a multi-channel
pipettor. The plate was then incubated overnight and the following steps are specific to
the described experiments.
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For transfection of PC-3 cells, 3x103 cells were first seeded in 100 µl complete
media in each well of a 96-well plate. The following day cells were transfected with either
miR-17-92a expression plasmid or scrambled expression plasmid, using the cells specific
protocol described previously. The media in all the wells was changed to fresh complete
media, 8-12 hours post transfection. To quantify the effect of miR-17-92a on PC-3 cell
proliferation, cells were incubated for 48 hours before addition of the MTS reagent. For
experiments used to monitor the effect of miR-17-92a expression on drug sensitivity,
treatment media was added 24 hours after transfection

3.8 Dual Luciferase 3 ’ U T R Reporter Assay

A dual luciferase reporter assay was used to determine if the predicted mRNA
targets were directly regulated by members of the miR-17-92a cluster. PC-3 cells
expressing miR-17-92a or Scr RNA were seeded into 96-well plates. The following day,
the cells were transfected with either control luciferase reporter plasmids or the
experimental plasmids. The cells were then incubated for 48 hours to allow for the
expression of luciferase. After 48 hours, luciferase activity was quantified using the LucPair assay kit (Genecopoeia) or the DualGlo (Promega) in conjunction with a plate reader.
The pEZX-MT06 plasmid (Genecopoeia cat # HmiT002135-MT01) contains the
first 500 nucleotides of the FGD4 3’UTR located immediately downstream of the firefly
luciferase gene (FGD4-3’UTRWT construct). This region contains one of the predicted
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binding sites for miRs -17 and -20a. Additionally, site directed mutagenesis was employed
to mutate three bases in the miR-17/20a seed region present in the cloned FGD4 3’UTR
to generate the FGD4-3’UTRMu construct. Nucleotides 80-GCACUUUA-90 were mutated
to 80-GCCAGUUA-90.
The 3’UTRs of LIMK1 and SSH1 were cloned into the pMirGlo plasmid (Promega).
The SSH1 3’UTR was amplified using the following primers (Forward: 5’GTAGACAGGAGTCCCGATAAG-3’, Reverse: 5’-TCACAAGAAGCACACACAC-3’). The
LIMK1

3’UTR

was

amplified

using

the

following

primers

(Forward:

5’-

GTAGACCGCTTCCCCTGC-3’, Reverse: 5’-CCTCCCTAAGTCATGGTCCC). Amplified
3’UTRs were ligated into pGEMT-Easy plasmids (A/T cloning vector). The 3’UTRs were
then excised from pGEMT-Easy by digestion using AccI and NotI-HF (NEB), then ligated
into the destination plasmid (pMirGlo), which was also digested with AccI and NotI-HF.
PC-3 cells or C4-2B cells were seeded into 96-well plates. The following day, the
cells were co-transfected with miR-17-92a or Scr RNA expressing plasmids along with
either control luciferase reporter plasmids or the experimental plasmids. The cells were
then incubated for 48 hours to allow for the expression of luciferase. After 48 hours,
luciferase activity was quantified using DualGlo (Promega) in conjunction with a plate
reader.
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3.9 Immunofluorescence Assay

For immunofluorescence assays of transiently transfected cells, 2 x 104 PC-3 cells
were seeded onto poly-l-lysine coated coverslips in a 24-well dish. The next day cells
were transfected as previously described with either the miR-17-92a expression plasmid
or the Scr control plasmid. Cells were incubated for 48 hours following transfection before
processing of coverslips.
For immunofluorescence assays of stably expressing cells, 2.5 x 104 cells were
seeded onto poly-l-lysine coated coverslips in a 24-well dish. Coverslips were incubated
for 48 hours before processing.
To process coverslips, growth media was removed from the well and coverslips
were washed three times with DPBS. Cells were then fixed in 4% paraformaldehyde
(Sigma Aldrich) for 10 minutes at room temperature. The coverslips were then washed
twice with DPBS and permeabilization of cell membranes was achieved by incubating
coverslips in DPBS containing 0.25% Tween-20 (Fisher) for 10 minutes at room
temperature. Cells were then blocked in DPBS containing 10% goat serum (Sigma
Aldrich), 2% BSA (Sigma Aldrich), and 0.1% Tween-20 for at least 1 hour at room
temperature. Primary antibodies were diluted in DPBS containing 2% BSA, and 0.1%
Tween-20, specific dilutions are listed in Table 8. Cells were incubated in primary antibody
dilutions for 1 hour, then washed with blocking solution 3 times (5 minutes/wash) while
rocking. Fluorescently conjugated secondary antibodies were diluted in DPBS containing
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0.1% Tween-20, specific dilutions are listed in Table 9. Cells were incubated in the dark
with diluted secondary antibodies for 45 minutes at room temperature. Non-specific
antibodies were removed by washing with DPBS containing 0.1% Tween-20 for 3 times
(5 minutes/wash) while rocking. To remove excess salts, coverslips were then washed
twice (3 minutes/wash) in 100mM sodium phosphate buffer (pH 7.4). Coverslips were
then removed from wells, excess buffer was wicked away using Kimwipes (KimberlyClark), and 20 µL of DAPI-Mount G (Southern Biotech) was applied to coverslip. Using
fine tip tweezers coverslips were slowly rotated allowing the mounting media to swirl and
coat coverslip. The coverslips were then inverted and held perpendicular on top of
Kimwipes, allowing mounting media to absorb into wipes. This process was repeated a
second time; the coverslips were then laid cell side up on clean Kimwipes for 2 minutes.
The coverslips were then flipped and mounted onto slides and placed in a dark drawer
for at least 12 hours. The coverslips were cleaned and sealed with clear nail polish.
Slides were imaged by confocal microscopy using a Leica SP-5 confocal
microscope paired with the Leica LAS-AF software suite. The LAS-AF software was also
used to quantify fluorescent intensities of individual cells.
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Table 8: Immunofluorescence Primary Antibodies and Stains
Target
Supplier
Host
Dilution
Antigen
Factor
1:350
FGD4
Genetex
Rabbit
1:500
E-Cadherin
Cell Signaling
Rabbit
Cell Signaling
Mouse
1:350
Ki67
1:350
pERK1/2
Cell Signaling
Rabbit

Table 9: Immunofluorescence Secondary Antibodies
Antige
n

Fluorophore

Compa
ny

Host

Mouse
IgG

488

Molecular
Probes

Goat

1:300

Mouse
IgG

Cy3

Jackson
Immuno

Goat

1:300

Rabbit
IgG

Cy3

Jackson
Immuno

Goat

1:300

Mouse
IgG

647

Molecular
Probes

Goat

1:300

Rabbit
IgG

647

Molecular
Probes

Goat

1:300
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Dilution

3.10 Flow Cytometry

PC-3 sublines expressing miR-17-92a or Scr RNA were grown to 60-80%
confluency and dissociated is DPBS containing 10 mM EDTA. Cells were collected and
washed in ice-cold DPBS, and fixed in 4% paraformaldehyde for 5 mins on ice. Cells were
agitated every minute to minimize clumping. After 5 mins 10 mL of cold HAM-F12K was
added to fixation solution and mixed. Cells were pelleted at 1,200 x g for 5 mins at 4˚C.
Cell pellets were resuspended in cold DPBS media containing 10% goat serum and
counted. Cells were blocked on ice for 20 minutes and 1 x 105 cells were transferred to a
LoBind microcentrifuge tube (Eppendorf) and pelleted. Cell pellets were then
resuspended in cold DPBS containing 2% BSA. Antibodies specific for e-cadherin were
added to cell suspensions to achieve a 200-fold dilution. Cells were incubated with
antibodies for 1 hour while rotating. Non-specific antibodies were removed by three
washes in blocking buffer. AlexaFluor488 conjugated goat anti-rabbit antibodies (Life
Technologies) were diluted 1:300 in in DPBS containing 1% BSA. Cells were incubated
in diluted secondary antibodies for 30 minutes while rotating. The labeled cells were
washed first in DPBS then 3 times in DPBS containing 0.05% Tween-20. The labeled
cells were detected using the BD Accuri Flow cytometer and analyzed with the BD
CSampler Software. In addition to the experimental samples, control samples were
prepared consisting of fixed but unlabeled PC-3 cells and PC-3 cells that were fixed,
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blocked, and incubated with only the secondary antibodies. The control cells incubated
without primary antibodies was used to establish the staining threshold. Events above
this threshold were considered positive for staining.

3.11 Cell Treatments

The small molecule inhibitor MK-2206 2HCl (Selleckchem) was used to inhibit the
activities of AKT1/2/3. PC-3 cells were seeded into 96-well plates and transfected the
following day. Twelve hours after transfection, media was replaced with 50 µL fresh
complete media. Twenty-four hours post transfection 50 µL of media containing MK-2206
was added to the 50 µL of media already present, resulting in inhibitor concentrations of
1, 5, or 10 µM. Alternatively, DMSO was diluted in the same manner and used as the
vehicle control. For treatment of LNCaP-104S cells media was prepared with charcoalstripped fetal bovine serum and without supplemented DHT. Cells were seeded in 100 µL
CS-FBS containing media supplemented with 20% conditioned maintenance media. After
the cells had attached, 24-30 hours, 80 µL was very slowly removed from each well. The
plate was held at an angle and 100 µL of fresh CS-FBS media was very slowly pipetted
onto the wall of the well. Note, this gentle pipetting method was used for all media
changes. Four hours after the media was changed, the cells were transfected. The
transfection media was replaced after 12 hours, and the cells were treated in a manner
similar to PC-3 cells. LNCaP-104S were treated with 0.5 µM, 1 µM, or 2.5 µM
concentrations of AKT inhibitor, MK-2206. DTX, CDX, VX680.
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3.12 Wound Healing Assay

PC-3 sublines expressing miR-17-92a or Scr RNA were seeded into wells of 6-well
plate in HAM F-12K media containing 5% fetal bovine serum. Cells were grown to
confluency (24-36 hours after seeding) and wounds were created with a micropipette tip.
The cells were washed twice with media, to remove debris and detached cells, before
continued incubation in media containing 5% fetal bovine serum. Wound healing was
observed at 14, 16, 20, and 24 hours, marks were made adjacent to each wound to permit
alignment of plate for re-imaging the same wound regions. Images of the wound were
taken under 10x magnification using a Nikon eclipse TE200 inverted microscope paired
with Nikon elements F 2.20 software. The average width of each wound was determined
using ImageJ software. small molecule

3.13 Xenograft Mouse Model

Xenograft experiments were conducted in 6-8 weeks old male NSG (NOD scid
gamma, NOD-scid IL2Rgnull, NOD-scid IL2Rgammanull, NSG) mice obtained from
Jackson Laboratory and maintained and treated under specific pathogen-free conditions.
Stable pool of PC-3 and M-12 Cells (2x106 / mouse) suspended in 0.1% matrigel in 100µl
volume were injected subcutaneously into the flank and tumor growth monitored for 60
days. Tumor growth was assessed by measurements with a caliper and volume was
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calculated as 0.52 × length × width × 2 as tumor grew. Tumors were harvested, as after
the specified time, tissue architecture examined by H&E staining of formalin fixed paraffin
embedded sections and used for RNA extraction for qRT-PCR of the matured miR-1792a miRNAs expressed in the tumor. Following is the detailed description of the method
of harvesting of samples, Mice were euthanized and tumors were promptly excised, nontumor tissue was trimmed, and the tumor was cut into multiple sections and washed with
ice cold DPBS. Samples designated for H&E staining were added to tubes containing icecold formalin. Samples designated for RNA extraction were cut into smaller sections and
added to tubes containing ice-cold HBSS (Hank’s buffered saline solution). Samples were
kept on ice until all tumors were harvested. The unfixed tumors in HBSS were then
transferred to cryotubes before being flash frozen in liquid nitrogen. Xenograft
experiments were performed using an animal protocol approved by the Animal Care and
Use Committee of the University of Central Florida.
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CHAPTER FOUR: RESULTS

4.1 MicroRNA Expression Associated with The Acquisition of Androgen Independence

The successful management of late stage metastatic prostate cancer remains a
difficult task. Clinicians turn to systemic treatments, which carry the greater reductions in
patient’s quality of life but can treat all metastatic sites. Because androgen is required for
normal growth and functioning of the prostate gland and also for development of cancer
androgen deprivation therapy (ADT) has become the mainstay for advanced prostate
cancer [52]. Although most patients initially respond to ADT by showing low PSA values,
they eventually develop more aggressive castration resistant prostate cancer (CRPC).
This has driven research into the mechanisms and biomarkers associated with androgen
independence. A number of studies indicated aberrant expression of miRNAs in CRPC
compared to androgen dependent (AD) prostate cancer cells [57, 58]. Several miRNAs,
such as miR-21, miR-125 and miR-32 are directly regulated by androgens in cells and
xenograft models [57, 59, 60]. Studies include comparative analysis between androgen
sensitive (AS) and -resistant prostate cancer cells, with or without treatment of AS cells
with androgens or normal vs. hormone refractory prostate cancer tissues, which only
provides steady state status of miRNA and gene expression. However, none of these
studies provide information on the mechanism of transition of androgen-sensitive or
46

dependent prostate cancer cells to antiandrogen resistant cells. In this study, we show,
for the first time alteration in expression of miRNAs and their target proteins as the cells
progress to antiandrogen resistance, some of which are not detectable in the established
AI cell line.

4.1.1 MicroRNA Expression Profile Differentiates Between Untreated LNCaP Cells and
Cells Treated with Casodex or Subjected to Androgen Withdrawal
We used genome-wide miRNA array (1113 unique primers) profiling approach to
identify specific miRNAs that are involved in development of resistance to Casodex
(CDX). A clonal subline of LNCaP cells LNCaP-104S (−104S) and its androgenindependent derivative LNCaP-104R1 (−104R1) were used for monitoring differential
expression of miRNAs upon treatment with CDX. LNCaP-104S cells are CDX-sensitive,
whereas LNCaP-104R1 cells are not despite expressing AR at a basal level higher than
LNCaP-104S cells [61]. LNCaP-104S cells require DHT for maintaining their AD status
but when treated with CDX for 3 weeks in CS-FBS (charcoal-stripped FBS), CDX
insensitive colonies develop that are independent of androgen (CDXR). During the first
week of both CS-FBS and CDX treatments, LNCaP-104S cells grew without significant
cell death, however, during the second week of CDX treatment about 60% cells died and
detached. From the residual 40% cells, half of the cell population remained viable during
the third week of CDX treatment. CS-FBS -treated cells did not show as much cell death
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during the second week of treatment and started to regrow during the third week of
treatment. Cell morphology also changed as they are treated with CDX and CS-FBS
(Figure 5). The cells adopted a neuroendocrine phenotype characteristic of LNCaP cells
exhibiting repression of the Androgen Receptor [62]. Cells viable after third week of
treatments were used for miRNA profiling experiments. Expression of AR in these cells
showed gradual reduction as the treatment progresses, but the PSA expression
increased, which suggests increased transcriptional activity of the residual AR in the
treated cells (Figure 6).
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Figure 5: Altered cell morphology during ADT
Images of LNCaP-104S cells before and during androgen deprivation or androgen blockade.
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Figure 6: Expression of AR and PSA in androgen sensitive and independent cells
Immunoblots displaying expression of Androgen Receptor (A) and PSA (B) in androgen sensitive -104S
cells, androgen independent -104R1, and -104S cells at 1 and 3 wks of ADT (left to right).
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We compared miRNA expressions in RNA extracts from untreated and CDX
treated -104S cells at 0 hr, 1wk and 3wks and untreated -104R1 cells (Table 10).
Table 10: Cell lines and treatments
Reference

Test/Reference

0hr
1wk CSFBS
3wks CSFBS
1wk CDX
3wks CDX
0hr

Cell Line
LNCaP-104S
LNCaP-104S
LNCaP-104S
LNCaP-104S
LNCaP-104S
LNCaP-104R1

Samples
Treatment
FBS-DHT 1nM
CSFBS
CSFBS
CSFBS/5μM CDX
CSFBS/5μM CDX
CSFBS

Time point
0 hr
1 wk
3 wks
1 wk
3 wks
0 wks

Hierarchical clustering of the normalized and log2 transformed expression data
(Additional File 1) showed 5 distinct clusters of miRNAs (Figure 7). Comparative analysis
between samples from different conditions using two samples Welch t-test with Log10
transformed data and p values of 0.05 showed significant miRNAs that are differentially
expressed between conditions (Figure 8: ). Volcano plot (V plots) of the t-test between
LNCaP-104S cells and all other samples showed 38 significant miRNAs, of which 27
miRNAs were up regulated and 11 down regulated compared to -104S (Figure 8: A).
Comparison between untreated -104S and -104R1 cells showed 24 significant miRNAs,
which includes 16 down regulated and 8 up regulated miRNAs in -104R1 (Figure 8: B).
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Figure 7: Hierarchical clustering of the data from genome wide miRNA profiling
Hierarchical clustering of the data from genome wide profiling of miRNAs in LNCaP Cells with or without treatment with CS-FBS and CDX.
Samples 1, 2: LNCaP-104R1, Samples 3-5: LNCaP-104S1, Samples 6, 7: LNCaP-104S 1 wk CDX treated, Samples 8, 9: LNCaP-104S 1 wk
CSFBS treated, Samples 10, 11: LNCaP-104S 3 wks CDX treated, Samples 112, 13: LNCaP-104S 3 wks CSFBS treated
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Figure 8: Volcano plots of the two samples t-tests of the normalized values of untreated and treated LNCaP cells.
Plots of the two samples t-tests of the normalized values of untreated and treated LNCaP cells as shown in Additional File 2.
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Differential expression of 17 significant miRNAs was observed between untreated
LNCaP-104S cells and -104S cells treated with CDX, of which 13 were up regulated and
4 were down regulated CDX treated cells (Figure 8: C). LNCaP-104S and -104S cells
treated with CSFBS also showed 9 up regulated and 5 down regulated microRNAs in
CSFBS treated cells (Figure 8D). Although -104R1 cells are CDX resistant there are
differences in miRNA expression when -104S cells were treated with CDX (Figure 8E).
T-test analysis showed 24 significant miRNAs of which 18 miRNAs were up regulated
and 6 down regulated in -104R1 cells. Difference in miRNA expressions was also noted
between -104S cells maintained in androgen-depleted condition and AI -104R1 cells.
Twenty-four significant miRNAs were identified of which 12 were up regulated and 12
down regulated in -104R1 cells (Figure 8F). Comparison between androgen depletion
and CDX treatment showed 5 significant miRNAs, 4 of which were up regulated and one
down regulated in CDX treated cells (Figure 8G).
Clustering analyses using log2 transformed fold change (FC) values of four
treatment conditions compared to -104S untreated cells showed two distinct clusters of
up and down regulated miRNAs, which includes 307 down regulated and 197 up
regulated miRNAs (Figure 9 and Additional File 3). Using Venn diagrams we identified
miRNAs that were commonly or uniquely deregulated in CSFBS and CDX treated cells
compared to untreated -104S cells or -104R1 (Figure 10). MicroRNAs that appeared in
multiple comparisons, including miR-146a, -302c, -18a/b, -20a/b) are highlighted.
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K-median clustering for the up-regulated miRNAs showed a trend of gradual
increase in median FC in miRNAs in some clusters (cluster 1, 4 and 9) and a gradual
decrease in some clusters (clusters 3, 7 and 8) from 1 week to 3 weeks treatments (Figure
11 and Additional File 4). In down regulated profile there is also a trend of gradual
decrease in median expression of miRNAs in some clusters (clusters 1, 2, 3 and 7)
(Figure 11B and Additional file 7). Of these lists, 100 miRNAs were chosen based on fold
change and/or the z score ≥3.0 or ≤ -3.0 for validation using qPCR
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Figure 9: Cluster analysis of fold change in expression of miRNAs in different treatment
conditions.
Hierarchical clustering of log2 transformed FC expression of miRNA in four groups, 1wk CSFBS, 1wk CDX,
3wks CSFBS and 3wks CDX (Table 10). Red and Green lines showing the expression patterns of 197 up
regulated and 307 down regulated miRNAs respectively (Additional File 3)
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Figure 10: Analysis of commonly and uniquely regulated miRNAs across treatment conditions
and LNCaP-104 sublines.
MicroRNA expressions from -104S cells at 3 weeks of treatment with CS-FBS only or CDX were compared
against untreated -104R and 104S sublines. miRNAs exhibiting at least a 3-fold difference in expression
from each comparison was used to construct Venn diagrams which identify common and unique alterations
in miRNA expression. Colored miRNAs were identified in more than one comparison.
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Figure 11: K-median cluster analysis for differentially expressed miRNAs at different treatment
conditions and time points
A) Up regulated miRNAs separated into 10 clusters based on similar trends in expression patterns are
depicted. MiRNAs in each cluster are showing a unique pattern of expression among 1wk and 3wks
treatments of both CDX and CSFBS. B) Down regulated miRNAs divided into 10 clusters based on similar
trends in expression are shown. MiRNAs in each cluster are showing unique patterns of expression during
1wk and 3wks treatments of CDX and CSFBS. Data shows median ± SD of expression of miRNAs in each
cluster.
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Figure 12: Comparative analysis of the expression of validated miRNAs during progression to
ADT and CDX resistance.
A) Volcano plots depicting significant miRNAs identified by two sample t-test in all treatment conditions
compared to untreated -104S cells (1st panel from left), in all CDX treated cells compared to untreated S
cells (2nd panel from left), in 3wks CDX treated cells compared to 1wk CDX treated S cells (3rd panel from
left) and in all CSFBS treated cells compared to untreated S cells (4th panel from the left). B) Venn diagram
using significant miRNAs identified in two sample t-tests (volcano plots) showing common and unique
miRNAs between all -104S CSFBS and -104S CDX treated cells.
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Figure 13: Comparative analysis of the commonly regulated miRNAs during progression to ADT
and CDX resistance.
List of commonly down-regulated (Left) and up-regulated (Right) miRNAs as noted in Venn diagram in all
treatment conditions, between 1wk CDX and 3wks CDX and between 3wks CDX and 3wks CSFBS cells.
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4.1.2 Validated Expression of miRNAs Revealed Distinct Differences in Expression in
Different Treatment Conditions
Analysis of qPCR data indicated a variable expression profile of a subset of
miRNAs in LNCaP cells exposed to CDX and/or androgen withdrawal (CSFBS) for
different time periods. Two sample Welch t-test with a p-value < 0.05 showed a significant
change in expression of 21 miRNAs in treated samples compared to the untreated -104S
cells (Figure 12A and Additional File 5). Comparison between -104S untreated and either
CDX or CSFBS treated samples identified 10 and 8 significant miRNAs respectively
(Figure 12A) Comparative expression analysis between CDX 1wk and CDX 3wks also
revealed significant change in expression in 3 miRNAs (Figure 12A). Venn Diagram of
miRNA expression profiles following CDX treatment and androgen withdrawal indicated
two common miRNAs (miR-146a and miR-759) but treatment specific differential
expression was observed with 8 and 6 unique miRNAs, in CDX and CSFBS treated
respectively (Figure 12B). Analysis of the up-regulated miRNAs revealed 10 miRNAs that
showed 2-fold or higher expressions in all treatment conditions and time points (Figure
12C). There are also 30 miRNAs that showed 2-fold or higher expression in more than
one treatment conditions. In the down regulated list, 9 miRNAs showed at least 2-fold
reduction in expression in all treatment conditions and 15 miRNAs with ≥2.0-fold down
regulation in more than one treatment conditions (Figure 12D).
Cluster analysis of log2 transformed FC in expression of 100 miRNAs showed three
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distinct clusters displaying common expression changes in 2 time points of two treatment
conditions. Two clusters contained miRNAs with increased expression and one cluster
containing down regulated miRNAs (Figure 14 and Additional File 6). K-median clustering
of the up-regulated miRNAs showed a distinct trend of gradual increase (clusters 1 [32%],
2 [26%] and 4[11%]) and gradual decrease (cluster 3 14%) in FC expressions as the
treatment progressed (Figure 15 and Additional File 7). Some of the miRNAs (21) showed
across the board up regulations (Table 11). Similarly, in the list of down-regulated
miRNAs a gradual decrease in expression (clusters 1 [18%] and 2 [21%]) could be noted
as the treatment progressed (Figure 16) and a subset of miRNAs (22) showed downregulation in all treatment conditions (Table 12). When compared with published
expression database there are supporting reports on expression patterns of specific
miRNAs in different types of cancer (Table 11 and Table 12). There are also opposing
reports on expression of miRNAs, which includes, miR-106a [63], miR-15b [64], miR-17
[65], miR-18 [66], miR-205 [67], miR-20 [68], and miR-7 [69] for down regulated miRNAs;
and let-7f-1 [70], miR-136a [71], miR-143 [72], miR-146a [73], miR-218 [74], miR-22 [75],
miR-222 [76], miR-29a [77], miR-34b [78], and miR-493 [79] for up-regulated miRNAs.
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Figure 14: Cluster analysis of fold change in expression of validated miRNAs in different
treatment conditions.
Hierarchical clustering of log2 transformed FC expression of miRNA in four treatment groups, 1wk CSFBS,
1wk CDX, 3wks CSFBS and 3wks CDX (Table 10). Red arrows and green arrows showing the expression
patterns of 21 up regulated and 22 down regulated miRNAs (Table 11 & Table 12), respectively.
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Figure 15: K-median cluster analysis of validated up-regulated miRNAs in different treatment
conditions
K-median cluster analysis of the validated miRNAs in different treatment conditions Up-regulated miRNAs
are divided into 5 clusters, which show unique trends of expressions. All miRNAs in each cluster show
similar trends in expression in all treatment conditions and time points. Data shows median ± SD of
expression of miRNAs in each cluster.
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Figure 16: K-median cluster analysis of validated down-regulated miRNAs in different treatment
conditions
K-median cluster analysis of the validated miRNAs in different treatment conditions. Down regulated
miRNAS are divided into 7 clusters each showing unique trend of expression pattern of miRNAs. All
miRNAs in each cluster is showing similar patterns of expression. Data shows median ± SD of expression
of miRNAs in each cluster.
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Table 11: Fold change in expression of up-regulated miRNAs in different treatment conditions
and time points and its relevance with published reports
miRNA ID

1wk CSFBS

1wk CDX

3wks CSFBS

3wks CDX

Expression in Other

∆ Change

∆Change

∆ Change

∆ Change

hsa-let-7f-1*

12.50

12.17

13.91

17.64

hsa-miR-136

3.69

3.44

5.16

4.30

hsa-miR-143

15.80

19.67

13.92

6.25

hsa-miR-146a

31.44

20.83

56.46

50.68

hsa-miR-218

4.64

2.33

18.44

11.49

hsa-miR-22

2.39

2.43

4.58

3.10

hsa-miR-22*

15.91

11.56

11.78

22.47

hsa-miR-222

3.65

1.99

7.05

4.63

hsa-miR-29A

2.09

1.58

4.60

4.24

hsa-miR-302a*

2.97

7.73

3.87

4.48

hsa-miR-3138

6.53

5.94

6.66

5.96

hsa-miR-3144-5p

11.25

4.39

4.47

8.53

hsa-miR-3192

8.70

2.11

5.52

5.71

-

hsa-miR-3199

1.25

4.54

2.71

6.76

-

hsa-miR-34b*

3.15

2.34

6.69

8.64

hsa-miR-493*

1.31

1.42

2.31

15.06

hsa-miR-548h

2.12

3.76

4.06

6.72

-

hsa-miR-548l

3.94

3.11

8.66

7.40

-

hsa-miR-548p

3.88

2.44

4.64

1.55

-

hsa-miR-548t

4.89

9.65

1.26

5.46

-

hsa-miR-664

3.81

4.01

5.16

5.05

Cancer

-

Thickness of arrows represents number of publications available corresponding to the expression pattern
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Table 12: Fold change in expression of down-regulated miRNAs in different treatment
conditions and time points and its relevance with published reports
1wk CSFBS

1wk CDX

3wks CSFBS

3wks CDX

Expression in

∆ Change

∆ Change

∆ Change

∆ Change

Other Cancer

hsa-miR-106a

-2.37

-3.18

-5.29

-9.40

hsa-miR-1244

-3.40

-8.55

-5.14

-3.38

hsa-miR-15b

-1.86

-2.02

-2.85

-3.33

hsa-miR-15b*

-2.42

-4.65

-3.83

-9.76

hsa-miR-17

-2.91

-3.37

-2.50

-24.99

hsa-miR-17*

-3.15

-3.13

-5.26

-3.94

hsa-miR-18a

-2.01

-4.36

-14.70

-14.13

hsa-miR-18b

-1.56

-2.28

-4.92

-21.36

hsa-miR-205

-6.33

-12.51

-12.06

-3.89

hsa-miR-205*

0.35

-1.34

-2.85

-3.23

hsa-miR-20a

-2.73

-3.31

-3.78

-4.12

hsa-miR-20a*

-1.78

-1.25

-2.64

-18.17

-

hsa-miR-20b*

-0.64

-0.56

-7.99

-4.60

-

hsa-miR-3131

-2.35

-2.97

-3.14

-3.41

-

hsa-miR-3185

-2.95

-3.24

-4.17

-5.76

-

hsa-miR-422a

-3.15

-3.15

-4.92

-6.87

-

hsa-miR-454

-0.58

-1.89

-3.28

-3.76

hsa-miR-518b

-2.64

-6.42

-5.61

-12.23

-

hsa-miR-596

-2.45

-3.94

-15.83

-12.71

-

hsa-miR-759

-13.05

-10.92

-6.17

-5.86

hsa-miR-7

-3.00

-5.23

-6.76

-11.08

hsa-miR-9

-2.64

-4.35

-4.53

-3.55

miRNA ID

-

-

-

-

NA: Not available. *denotes the star strand, which is currently designated as -3p or -5p. Thickness of arrows
represents number of publications available corresponding to the expression pattern
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4.1.3 Involvement of miRNAs in Specific Cellular Processes Which Differ Between
Treatment Conditions
MicroRNAs exhibiting up regulation or down regulation in all treatment conditions
compared to untreated -104S cells (Table 11 and Table 12), were used for function and
disease relevance to understand the possible alterations in the cellular processes as
LNCaP cells progressed towards androgen withdrawal and AR antagonist resistance. We
used RT-PCR FC values of the up regulated or down regulated miRNA for the analysis
using IPA software (Ingenuity Systems). Based on -log (p-values) with -values <0.05, a
percentage of miRNAs were assigned to certain disorder or cellular processes (Figure 17
and Figure 18). When the functional profiles of the up-regulated miRNAs were compared,
there is a decrease in the percentage of miRNAs involved in cancer, dermatological
disease, and hematological disease between 3wks and 1wk CDX treated cells whereas
an increase in the percentage of miRNAs involved in endocrine system disease,
gastrointestinal disease hepatic system disease, reproductive system disease and
metabolic disease in 3wks CDX treated S cells compared to 1wk CDX treated cells
(Figure 17) In cells subjected to androgen withdrawal, there are also differences in
percentage of miRNAs in different cellular processes between 1wk and 3wks treatments,
which show a reduction in hematological diseases, cellular development, and
reproductive system disease. An increased involvement of miRNAs in a variety of cellular
processes also was noted in 3wk CSFBS treated cells, which includes cell death and
survival,

cell

movement,

endocrine

system
68

disease,

gastrointestinal

disease,

hematological disease, hepatic system disease and metabolic disease (Figure 17).
In the list of down-regulated miRNAs, there is an increase in percentage of
miRNAs involved in cell morphology, cell movement, dermatological disease,
gastrointestinal disease, renal urological disease, and reproductive system disease as
cells progressed from 1wk to 3wks CDX treatment. A decreased percentage of down
regulated miRNAs in specific cellular processes also could be noted in these cells, which
includes cellular development, endocrine system disease, hepatic system disease, tumor
morphology and inflammatory response. Androgen withdrawal for 1wk to 3wks also
showed changes in percentage of miRNA involvement (Figure 18). An increased
percentage of down regulated miRNAs involved in cancer, cell death and survival,
dermatological disease, endocrine system disease, gastrointestinal disease, metabolic
disease, and tumor morphology is noted in 3wks CSFBS treated cells. 3wks androgen
withdrawal also showed a decrease in miRNA percentage involved in cell growth and
proliferation, cell movement, cell-cell signaling, DNA replication and repair and renalurological disease (Figure 18).
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Figure 17: Correlation of ADT induced miRNAs with previously published functions
Analysis of association of deregulated miRNAs with canonical pathways and cellular processes. Pie charts
showing the percentage of validated up regulated miRNAs in various cellular processes based on the
published reports. Upper panel depicts the percentage of miRNAs involved in cellular processes and its
changes during 1wk and 3wks treatments with CDX. Lower panel shows changes in the percentage of
miRNAs involved in cellar processes during 1wk and 3wks treatments with CSFBS.
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Figure 18: Correlation of ADT repressed miRNAs with previously published functions
Analysis of association of deregulated miRNAs with canonical pathways and cellular processes. Pie charts
showing the percentage of validated down regulated miRNAs in various cellular processes. Upper panel
illustrates the changes in the percentage of miRNAs involved in cellular processes during 1wk and 3wks
treatment with CDX. Lower panel represents changes in the percentage of miRNAs involved in cellular
processes during 1wk and 3wks treatments with CSFBS.
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The in silico function analysis of the target miRNAs in different treatment conditions
indicated a complex interaction of a network of miRNAs and their target proteins in these
cells which rendered them adaptive to the androgen withdrawal and treatments with AR
antagonists. Next, we analyzed the network of interactions among target miRNAs. We
used the log2 transformed FC values of the subset of validated miRNA (Table 11 and
Table 12) for analysis of the functional interrelationship among miRNAs (Figure 19). The
network for up-regulated miRNAs and its putative targets in 3wks CDX showed that miR3192 directly and miR-218 indirectly through DEAD box protein DDX20 target p53. MiR146a also directly regulates a number of Toll-like receptors (TLR1, TLR9 and TLR10),
cytokine receptors and its associated proteins (IL1R1, IL12RB2, IL1RAP) and chemokine
receptors (CXCR4, CCR3) (Figure 19A). In addition, miR-146a directly targets a number
of growth factors and cytokines (Figure 19A). These miR-146a targets are also shown in
the up-regulated network of 3wks CSFBS, in addition to BRCA, which is a direct target of
miR-146a (Figure 19E). MiR-3192 targeting of p53 is also noted in 3wks CSFBS but not
of miR-218 (Figure 19E). As noted in the networks, p53 also regulates a number of
miRNAs, such as, miR-29b-3p, miR-22-3p, miR-22-5p and miR-221-3p (Figure 19A and
E). When the networks are overlaid with diseases, a number of miRNAs in the upregulated list of both 3wks CDX and 3wks CSFBS showed involvement in a variety of
cancers including pancreatic cancer, endocrine gland tumor, prostate cancer, ovarian
tumor, mammary tumor, cervical cancer and epithelial neoplasia (Figure 19B and F). In
the list of down-regulated miRNAs there is direct targeting of E2F2, E2F3, MAP3K12,
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FXR1 and AR interacting nuclear protein kinase HIPK3 by miR-17-5p. MiR-16p also
directly targets BCL2L2, cell death suppressor BNIP2, EGFR, RAB21 and single strand
purine rich DNA binding protein PURA (Figure 19C and G) in both 3wks CDX and 3wks
CSFBS treated cells. Also a number of miRNAs in the down regulated list down regulate
a number of common targets, such as E2F3 is targeted by miR-1244, miR-596, miR-18a5p, miR-16-5p and miR-17-5p. EGFR is also targeted by miR-7a-5p and miR-16-5p.
Overlay of diseases on networks revealed a distinct association of miR-17-5p, with
various cancers including prostate cancer, breast cancer and pancreatic cancer and
endocrine gland tumors. An association of miR-16-5p with prostate cancer, pancreatic
cancer, pituitary cancer and endometrial cancer also could be noted (Figure 19D and H).
These networks indicate a complex interplay of microRNAs and proteins during
development of resistance of LNCaP cells to androgen withdrawal and treatment with
CDX.
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Figure 19: Analysis of miRNA-regulated network of interacting partners involved various
signaling pathways.
A) Log2 transformed FC values of 21 up regulated miRNAs were imported into IPA software and a network
for interacting miRNAs and their direct target proteins and proteins that target any of the up regulated
miRNAs was generated for 3wks CDX treated cells. Red symbols denote miRNAs. Proteins include growth
factor/cytokines, enzymes, kinases, phosphatases, peptidases, translational regulator, transcriptional
regulators, and transporters. B) The network in A is overlayed with disease relationship showing association
of miRNA and protein interactions with various types of cancer. C and D) Regulatory network of the log2
transformed FC values of 22 down regulated miRNAs and their target proteins in 3wks CDX treated cells
(C) and overlay of disease association of the miRNA-protein regulatory network (D). Green symbols
represent down regulated miRNAs. E and F) Regulatory network of log2 transformed FC values of the up
regulated miRNAs and their target proteins in cells treated with CSFBS for 3wks (E) and an overlay of
disease relationship with the regulatory network in E. Red symbols represent miRNAs. G and H) Regulatory
network of log2 transformed FC values of the down regulated miRNAs and their target proteins in cells
treated with CSFBS for 3wks (G) and an overlay of disease association with the regulatory network in G
(H). Click here for larger image.
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4.2 Identification of Genes Effected by miRNAs Deregulated in the Transition to
Androgen Independence

4.2.1 Target Identification of the Subset of miRNAs Revealed Potential Activation and/or
Inactivation of a Number of Proteins Involved in Different Signaling Networks
A total of 21 up regulated and 22 down regulated miRNAs in all treatment
conditions were used for identification of protein targets using IPA, miRDB and
TargetScan software. Venn diagram of the putative targets of up-regulated miRNAs
derived from the network generated using the IPA software showed 27 proteins that are
common in all treatment conditions (Figure 20). A number of which are known tumor
suppressors such as BRCA1 [80], TP53 [81], RAD54L [82], IRF5 [83], DUSP2 [84], IKK1
or CHUK [85]. Other targets of up regulated miRNAs in different treatment conditions also
includes proteins that inhibit tumor progression, such as DNMT3A [86], FADD [87], pTEN
[88], FOXO3 [89], DDX20 [90] and PA2G4 (EBP1)[91]. There are also 41 common targets
of the down-regulated miRNAs in all treatment conditions (Figure 21). Some of the targets
are known oncoproteins, which includes EGFR [92], VEGFA [93], ZBTB7 (POKEMON)
[94], acid phosphatase 2(ACP2) [95] and NFKB1 [96]. Additionally, proteins that are
overexpressed in cancer cells are among the targets of down-regulated miRNAs in
different treatment conditions, which includes Wnt3A [97], PPARα [98], UCP2 [99], CSF1
[100], and MED1 [101].
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Figure 20: Analysis of treatment specific targets regulated by up-regulated miRNAs
Venn diagram showing specific targets that are potentially regulated by miRNAs that are up regulated in
different treatment conditions. Putative targets were identified based on the regulatory network generated
by IPA software.
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Figure 21: Analysis of treatment specific targets regulated by up-regulated miRNAs
Venn diagram depicting predicted targets regulated by the down-regulated miRNAs in different treatment
conditions. Targets were identified based on the regulatory network using IPA software.

77

4.2.2 Targets of miRNAs Showed the Predicted Expression Profiles in LNCaP Cells
Subjected to Androgen Withdrawal and CDX Treatment
Further identification of the targets of selected miRNA (Table 11 and Table 12)
was conducted by miRDB and TargetScan database search and proteins that are
regulated by one or multiple miRNAs from our list and received higher target scores in
either or both searches are presented in (Table 13 and Table 14). The selected proteins
that are regulated by the up-regulated miRNAs include TNF receptor associated factor 6
(TRAF6) [102], interleukin receptor associated kinase1 (IRAK1), BCL6 co-repressor-like
1(BCORL1) [103], Cbl [104], neuro oncological ventral antigen1 (NOVA1) [105], coiled
coil domain containing 67 (CCDC67)[106], NET1 [107], ZFAND1(Acc.# NM_024699),
RGS6 [108], CDKN1B (p27Kip1) [109], IGFBP5 [110], and RNASEL [111] (Table 13). The
proteins that are potentially regulated by the down-regulated miRNAs include, ABHD3
[112], FGD4 [113], CCNJ [114], CHAMP1 [115], Myb [116], PIK3CD [117], VEGFA [118],
SPOPL [117], RAB9B [119], EGFR [120], E2F1 [121], and DOK4 [122]. Western blot
analysis confirmed the predicted expression profiles of some of the targets. Expression
of Cbl, p27Kip1, TRAF6, IRAK1, and ZFAND1 were significantly and progressively down
regulated in cells treated with CDX or subjected to androgen deprivation (Figure 22).
Similarly, expression of FGD4, VEGFA, EGFR, DOK4 and ABHD3 were up regulated to
moderate to high levels in cells treated with CDX or CSFBS (Figure 23).
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Table 13: Predicted mRNA Targets of Up-Regulated miRNAs
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Table 14: Predicted mRNA Targets of Down-Regulated miRNAs
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Figure 22: Comparative analysis of target protein expression in LNCaP sublines in different
treatment conditions.
Western blot analysis of the target proteins identified using TargetScan and miRDB online prediction tools
for a particular miRNA (shown in Table 2). Total proteins from -104S cells untreated and treated for different
times, and -104R1 cells untreated were used for immunoblotting using anti-cbl (A), -p21Kip1 (B), -TRAF6
(C), -ZFAND1 (D) and –IRAK1 (E) antibodies. Upper panel shows representative images of the western
blots. Bottom panel shows densitometric analysis of relation protein expression. Data shows mean ± SD of
at least three independent experiments. *p < 0.05, **p < 0.01, significance was calculated between LNCaP104S untreated vs. specified treated cells.
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Figure 23: Comparative analysis of target protein expression in LNCaP sublines in different
treatment conditions.
Western blot analysis of predicted target proteins regulated by down regulated miRNAs (shown in Table 3).
Total proteins from all treated and untreated cells were used for immunoblot analysis using anti- FGD4 (A),
ABHD3 (B), -DOK4 (C), VEGFA (D), and EGFR (E) antibodies. Upper panel shows representative images
of the western blots. Bottom panel shows densitometric analysis of relation protein expression. Data shows
mean ± SD of at least three independent experiments. *p < 0.05, **p < 0.01, significance was calculated
between LNCaP-104S untreated vs. specified treated cells.:
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4.3 miRNAs Deregulated in Both Androgen Independent Cells and Clinical Specimens

4.3.1 miRNA Expressions Deregulated in Human Prostate Tumors
Our studies on genome-wide profiling of miRNAs using LNCaP cell culture model
showed down regulation of miR-17-92a cluster in anti-androgen resistant cells [123]. In
this study, validation of expression profiles in clinical specimens also showed loss of
expression of this cluster miRNAs. We used macro-dissected prostate tumor tissues and
corresponding uninvolved areas to monitor expression of mature miR-17, -18a, -20a, 19a, -19b and -92a miRNAs. Patients were selected based on specific criteria including
no prior treatments, Gleason Scores, pre-surgical PSA and local invasion; and based on
CAPRA-S score [56] stratified into low, medium and high risk of biochemical recurrence
(Table 15). Normalized fold-change (FC) expression analysis showed a distinct down
regulation/loss of expression of all members of the miRNA cluster in 58-73% of the cases
tested (Figure 24A). Correlative analyses of miRNA expressions, with at least a 1.5-fold
change in expression, with risk assessment showed down-regulation of the cluster in 35%
of low risk cases (CAPRA-S ≤ 2) and up-regulation in 19% of the cases. For patients with
a higher risk (CAPRA-S ≥ 3), the percentage of patients with down-regulated miR-17-92a
miRNAs showed no change at 34% (Figure 24B). However, this analysis did identify a
distinct reduction in the percentage of patients with up-regulation, at only 9% for the
cluster; additionally, no patients with CAPRA-S ≥3 displayed increased expression of
miR-19b or miR-92a (Figure 24B). Further correlating expressions with CAPRA-S risk
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showed that four, five or all miRNAs were down regulated in 67% of the cases in the highrisk and medium-risk groups (Table 16). Reduced expression of three, two or one
miRNAs was noted in the rest of the 33% cases in the high or medium-risk groups. In the
low risk group, four, five or all miRNAs were down regulated in 50% of the cases while
loss of one, two or three miRNAs were noted in the other 50% of the cases. Analysis of
endogenous expression of these miRNAs in prostate adenocarcinoma and BPH cell lines
also showed reduced expression of most of the miRNAs in cancer cells compared to BPH
cells (Figure 24C). This observation led to the subsequent experiments to understand the
functional significance of the loss of expression of miR-17-92a cluster in phenotypic
changes in prostate cancer cells.
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Table 15: Patient criteria and assessment of the risk of recurrence
Patient
PSA preGleason CAPRA-S
Risk
#
surgery
Score
score
1
14.3
3+2=5(IV)
2
low
2
5.9
3+3=6
2
low
3
4.3
3+3=6
2
low
4
8.2
3+4=7
2
low
5
7.8
3+4=7
2
low
6
8.8
3+4=7
2
low
7
6.6
3+4=7
2
low
8
3.7
3+4=7
2
low
9
23.3
3+3=6
3
medium
10
6.3
3+4=7
3
medium
11
6.2
3+4=7
3
medium
12
4.7
3+4=7
3
medium
13
5.1
3+3=6
4
medium
14
87.4
3+3=6
4
medium
15
9.8
3+4=7
4
medium
16
9.4
3+4=7
4
medium
17
8.8
3+4=7
4
medium
18
5.4
4+3=7
4
medium
19
6.5
3+4=7
5
medium
20
6.5
3+4=7
5
medium
21
4.8
3+4=7
7
high
22
14.9
3+4=7
7
high
23
13.9
4+3=7
7
high
24
5.6
4+3=7
8
high
25
51.8
4+5=9
9
high
26
51.8
4+5=9
9
high
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Figure 24: Expression profiles of the miR-17-92a cluster miRNAs in clinical samples and cell lines
Relative expression of miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a. Raw data have been normalized to the average of 3
reference genes (RNU43, U6 snRNA, U1 snRNA). A) Average fold change(FC) in expression of entire miR-17-92a cluster (Bars) in patient
tumors compared to matched uninvolved adjacent tissues. Open triangles denote the fold change values of miR-17, miR-18a, miR-19a, miR20a, and miR-19b. Filled triangles denote values of miR-92a. B) Dot plots displaying the percentage of patients having FC values of ≥1.5 for
each miRNA. Bars identify the average value for the cluster. Red and Blue symbols indicate up- or down- regulation, respectively. Patients were
separated into 2 risk groups based on CAPRA-S score (Low= ≤2, Higher= ≥3). (A and B) All values are an average of two separate analyses.
C) Fold change in expression of miR-17-92a cluster miRNAs in benign and cancerous prostate cell lines. LNCaPS: LNCaP104-S cells. Data
show average of three separate analyses.

86

Table 16: Correlative analysis of miRNA expression with risk of recurrence

Risk

All
miRNAs

Five miRNAs

Four miRNAs

Three
miRNAs

Two/One
miRNAs

High
(6)

2

1 (miR-17, -18a,
-20a, -19b, -19a

0

2 (miR-92a)

Medium
(12)

4

1 (miR-17, -19a,
-19b, -20a, 92a)

1 (miR-18a, 19b, -20a)

3 (miR-92a,
and -20a)

Low
(8)

1

2 (miR-17, -19a,
-19b, -20a, 18a/or -92a)

1 (miR-18a, 19a, -20a and 92a)
3 (miR-17/or18a, -19a, 19b/or -20a/or 92a)
1 (miR-17, -18a,
-20a, -92a)

1 (miR-19a, 17/or -18a/or 19b/or -20a)

3 (miR-18a/ 19b/ or -92a)
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4.4 Functional Relevance of miR-17-92a Cluster in Prostate Cancer

In this study, we evaluated the functional significance of miR-17-92a cluster
miRNAs in prostate cancer progression and resistance to chemotherapeutic agents.
Because miRNAs are integrated into positive and negative regulatory loops of gene
expression, it is important to study the expression and functions of all members of miR17-92a cluster miRNAs concurrently to mimic the in vivo environmental setting. This
would help understanding the consequence of deregulation of miR-17-92a cluster as a
whole. Our expression analysis data provide evidence of an association of reduced
expression of miR-17-92a cluster members with higher potential of biochemical failure,
as indicated by higher CAPRA-S scores, of the majority of prostate cancer patients tested.
To our knowledge, this is the first report on the expression of the miR-17-92a cluster in
annotated prostate cancer clinical specimens.

4.4.1 Expression of miR-17-92a Cluster Altered Cell Morphology and Reduced
Expression of Actin Cytoskeleton Modulatory and Cell Cycle Regulatory Proteins
We generated sublines of PC-3 prostate cancer cells that overexpress all mature
miRNAs of the miR-17-92a cluster compared to the control cells expressing scrambled
(Scr) RNA upon transfection with the precursor miRNAs (Figure 26A). The extent of
expression was increased between 1.3-2.5-fold, a level comparable to that was detected
in BPH cells. We intended to express all miRNAs in the cluster simultaneously instead of
single miRNAs to mimic the physiological condition and study the combinatorial effects.
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Overexpression of all miRNAs changed the morphology of PC-3 cells from spindle shapes
to a more adherent cobblestone type (Figure 25).
Expression of these miRNAs resulted in 25%-40% reduction in concentration of
some of the computer algorithm based predicted target proteins FGD4, LIMK1, SSH1 and
cyclin D1, which contain one or more binding site(s) of miR-17 and -20a at the 3’-UTR
(Figure 27A) but no other miRNAs of the cluster. PC-3 cells were used to confirm the
direct binding of miR-17 and -20a to the predicted sites of one of the targets, FGD4.
Luciferase reporter assays were done upon transient co-transfection of the miR-17-92a
precursor construct plus a luciferase construct containing a fragment (bases from position
80-90) of FGD4 3’-UTR, in PC-3 cells.

Figure 25: Altered morphology of PC-3 cells expressing miR-17-92a cluster
Differential interference contrast (DIC) images of PC-3 cells expressing Scr RNA (left) or miR-17-92a cluster
miRNAs (Right). Scr RNA expressing cells retain parental PC-3 cell morphology, whereas stable expression
of miR-17-92a cluster miRNAs induced a more adherent phenotype and reduced the number of spindlelike cells (Right) Scale bar: 10 µm.
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Results showed 54% inhibition of translation of FGD4 mRNA, which could be
rescued by mutating miR-17 and -20a binding sites at the 3’-UTR (Figure 27D).
Additionally, LIMK1 and SSH1 3’UTRS resulted in a 45% and 25% reduction in luciferase
activity, respectively. Taken together, these results confirmed that overexpression of miR17-92a reduced synthesis of protein involved in activation of RhoGTPase pathway
(FGD4) [124], actin cytoskeleton reorganization (LIMK1) [125, 126] and cell cycle
regulation (SSH1, Cyclin D1), that are often hyper-activated or over-expressed in
advanced prostate cancer [127-129]. Our results showing inhibition of expression of
Cyclin D1 prompted us to study cell proliferation and activation of the signaling pathways
that promote cell proliferation. Using western blots, we detected expression of
phosphorylated ERK1/2, phosphorylated AKT and phosphorylated AKT substrate,
PRAS40, as markers for activation of MAP Kinase and AKT pathways in whole cell lysates
of PC-3 cells expressing miR-17-92a cluster miRNAs. Our analyses showed a significant
reduction (35%-55%) of these proteins in cells expressing miR-17-92a miRNAs compared
to control cells expressing Scr RNAs (Figure 28A and B). Furthermore, no significant
changes in total protein concentrations were observed for AKT1, ERK1/2, or PRAs40
(Additional File 8). A reduced expression of p-ERK1/2 in miR-17-92a miRNAs expressing
cells as detected by immunofluorescence analysis, confirmed the western blot data
(Figure 29A). The percentage of cells expressing Ki-67 antigen, a cell proliferation marker
[130], was also reduced significantly in transiently transfected PC-3 cells upon expression
of miR-17-92a (63% vs. 83%) compared to Scr RNA expression as detected by
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immunofluorescence (Figure 29A). Comparative MTS assays showed a significantly
reduced (20%-30%) growth of transiently transfected LNCaP104-S and PC-3 cells upon
expression of miR-17-92a miRNAs (Figure 29B).

Figure 26: Expression of miR-17-92a cluster in transfected cells
Quantitative PCR analysis of the expression of the members of the miR-17-92a cluster in stably transfected
PC-3 (A) and M12 (B) cells expressing miR-17-92a miRNAs of Scr RNA. Data representmean±SD of 3 or
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more independent analyses.
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Figure 27: Expression of miR-17-92a cluster in prostate cancer cells reduced expression of the
putative target genes.
A) Predicted binding sites of miR-17, and miR-20a in the 3’UTRs of the target mRNAs B) Representative
images of immunoblots of FGD4, cyclin D1, LIMK1, and SSH1 in PC-3 cell lysates showing reduced
expression of all of these predicted targets upon expression of miR-17-92a. GAPDH and α-tubulin were
used as the loading controls. C) Densitometric analysis of protein concentrations normalized to the internal
controls. Data shows mean±SD of three independent analyses. *p=0.0004, **p=0.0004; ***p=0.003 •p
<0.0001. D and E) Luciferase reporter assays confirming that miR-17a and -20a directly target FGD4 (D),
SSH1 and LIMK1 (E) through binding to the specified seed sequence at the 3’UTR. PC-3 cells were cotransfected with the luciferase constructs containing a nonspecific DNA sequence, a fragment of wild type
3’ UTRs or a fragment of FGD4 3’ UTR containing mutations at the miR-17/-20a seed sequence (D only)
along with a plasmid expressing either miR-17-92a miRNAs or scrambled RNA. Data represent the
mean±SD of three independent experiments. * p=0.001.
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Figure 28: Expression of miR-17-92a miRNAs reduced activation of MAPK and AKT pathways.
A) Immunoblot analysis showing reduced phosphorylated ERK1/ERK2, -AKT, -PRAS40 (AKT substrate), and -Cofilin (LIMK1 substrate) in
lysates from PC-3 cells stably expressing miR-17-92a cluster compared to cells expressing Scr RNAs. GAPDH or α-tubulin was used as the
loading controls. B) Densitometric analysis of the phosphoprotein concentrations normalized to internal controls. Data represent mean±SD of
three separate experiments. *p=0.0003, **p=0.0001, ***p=0.007, •p=0.008.
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Figure 29: Expression of miR-17-92a miRNAs decreased cell proliferation.
A) Immunofluorescence analysis showing reduced expression of Ki-67 proliferation marker and phosphorylated ERK1/2 in PC-3 cells transiently
expressing miR-17-92a miRNAs compared to control cells. Scale bar: 25µm. B) Cell proliferation assay showing reduced cell growth in miR-1792a cluster miRNA expressing cells. LNCaP104-S (LNCaPS) or PC-3 cells were transiently transfected with DNA constructs for Scr RNA or
miR-17-92a precursor miRNAs and cell proliferation at 72 hr were detected by MTS assays. Data represent mean±SD of six independent
experiments in triplicates. *p<0.0001; **p=0.0001
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4.4.2 Expression of miR-17-92a Cluster Delayed Tumorigenicity and Reduced Tumor
Growth
We generated stable sublines expressing miR-17-92a miRNAs or Scr RNA of
another metastatic prostate cancer cell line, M-12 (Figure 26B). Both PC-3 and M12
transfected sublines expressing miR-17-92a miRNAs or Scr RNAs were used for
experiments on tumor growth in xenograft models. Cells were injected into the flanks of
humanized NSG mice and tumor growth monitored for 55 days. The results showed a
significant reduction in tumor volume (35%-53%) in mice injected with PC-3 and M12 cells
expressing miR-17-92a cluster compared to the tumors in mice injected with cells
expressing Scr RNAs (Figure 30A, B, C, D, E and F). A delayed tumorigenesis was also
noted in mice injected with prostate cancer cells expressing miR-17-92a cluster (Figure
31). Quantitative RT-PCR Analysis of expression of the matured miRNAs in tumor tissues
showed a sustained maintenance of the increased (>2.0 to >7.0 fold) expression of all
cluster miRNAs (Figure 30G and H). In general, animals with both PC-3 and M-12 miR17-92a tumors survived longer than animals with tumors with Scr RNA. Some of the M12miR-17-92a tumor bearing animals were alive till 80 days post injection and showed
sluggish or stunted tumor growth (data not shown)
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Figure 30: Expression of miR-17-92a cluster miRNAs reduced tumor growth in xenograft models.
Transfected sublines of PC-3 and M12 cells stably expressing miR-17-92a miRNAs or Scr RNAs were used to establish tumors in the flank of
NSG mice. (A and B) Comparison of tumor volumes at 55 days post injection for PC-3 cells (A) or M12 cells (B). Data represent mean tumor
volume±SD of 4 animals/group. *p=0.002 (A); **p=0.003 (B). (C-F) Representative images of tumors in situ developed from PC-3 cells (C and
D) or M12 cells (E and F). Scale bar: 10mm. (G and H) Quantitative PCR showing sustained expression of the miR-17-92a cluster miRNAs in
PC-3 and M12 tumors compared to the tumors developed from control cells expressing Scr RNAs. Data show mean expression ±SD of 4
animals/group
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Figure 31: Progression of tumor growth in mice
Mice were injected with PC-3 or M12 cells stably expressing miR-17-92a cluster miRNAs or Scr RNA and
tumor growth monitored for 55-57 days by tumor volume measurement.

4.4.3 Expression of miR-17-92a Inhibited Cell Migration and EMT
Previously, we noted a change in cell morphology upon restored expression of
miR-17-92a miRNAs. To understand the contribution of miR-17-92a cluster expression to
changes in cell behavior and phenotypes, we tested cell migration and expression of EMT
markers such as, vimentin [131], Twist1 [132], Slug [133], TCF8/ZEB1 [134] and ncadherin [135] in PC-3 stable sublines expressing miR-17-92a miRNAs. The bright field
images and quantification of the distance traversed by the cells in scratch assays after
24h of incubation showed a significantly slower rate (25%-27%) of migration upon
expression of miR-17-92a compared to the control cells expressing Scr RNAs (Figure
32A and B). This observation was supported by the immunoblot assay results showing
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significantly reduced expressions of n-cadherin, vimentin, Twist1, Slug, and TCF8/ZEB1
in these cells compared to the control cells (Figure 33A and B). Conversely, increased
expression (3.2-fold) and surface localization (22%) of the epithelial maker e-cadherin
[136] was noted in PC-3 cells upon expression of miR-17-92a as determined by western
blots (Figure 33A and B) and flow cytometric analysis (Figure 33C and D). Our results
demonstrate a phenotypic conversion of the highly aggressive PC-3 cells to a more
adherent type of cells with a reduced migration rate.

Figure 32: Expression of miR-17-92a cluster miRNAs inhibited migration
Migration was compared between PC-3 cells stably expressing miR-17-92a or scrambled RNA. (A and B)
Migratory properties of cells were tested through wound healing assays at 14 and 24 hours after wound
formation. The width of each wound was measured at three areas using light microscopy. Three wounds
were made in each dish and the experiment was conducted in triplicate. A) Representative images of
comparative migratory rates. Scale bar: 200m. B) Relative rates of migration at 14 and 24 hours. Data
represent mean±SD of three different experiments in triplicate wounds. *p=0.002; **p= 0.0004.
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Figure 33: Expression of miR-17-92a cluster miRNAs promoted an epithelial phenotype in
prostate cancer cells.
Expression of EMT markers were compared between PC-3 cells stably expressing miR-17-92a or Scr RNA.
(A-D) Expression of miR-17-92a cluster in PC-3 cells promoted a switch from EMT to MET phenotype A)
Representative images of the immunoblots of EMT markers. GAPDH or α-Tubulin was used as internal
controls. B) Comparative analysis of EMT marker expression showing decreased expression of EMT
markers but increased expression of the epithelial marker e-cadherin. Values were normalized to internal
controls. Data represent mean±SD of three separate experiments. *p=0.005; **p=0.00006; ***p=0.004;
•p=0.00002; ••p=0.001; •••p=0.00002. E) Overlay of a two-parameter histogram of the cell population
exhibiting surface expression of e-cadherin. Result shows increased surface expression of e-cadherin in
PC-3 cells expressing miR-17-92a cluster miRNAs. F) Quantification of the transfected PC-3 cells
expressing e-cadherin on the cell surface as determined by flow cytometry showing a 22% increase in the
cells expressing e- cadherin upon expression of miR-17-92a cluster miRNAs.
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4.4.4 Expression of miR-17-92a Cluster Improved Drug Sensitivity of Androgen
Dependent and Castration Resistant Prostate Cancer Cells
Our previous studies showed down-regulation of miR-17-92a cluster miRNAs in
LNCaP104-S cells as they developed resistance to Casodex (CDX) [123]. Here we
examined the involvement of miR-17-92a cluster in acquisition of CDX resistance of
LNCaP104-S cells. We used androgen-dependent LNCaP104-S cells transiently
transfected with pre miR-17-92a cluster DNA, and treated with CDX singly and in
combination with the pan-AKT inhibitor (AKTi) (MK-2206 2HCl), or docetaxel (DTX). As
noted earlier, expression of miR-17-92a cluster miRNAs reduced the number of viable
cells upon vehicle treatment compared to the Scr RNA expressing cells (Figure 34A).
Viability assays after single and combination treatments showed a synergistic effect of
expression of miR-17-92a cluster and CDX treatment on the number of viable cells
(Figure 34A). Treatment with DHT (10nM) showed an increased number of metabolically
active cells expressing Scr RNAs whereas expression of miR-17-92a miRNAs made
these cells less responsive to DHT (Figure 34A). LNCaP104-S cells expressing miR-1792a miRNAs also showed an increased sensitivity to DTX at 1nM and 5nM concentrations
compared to control cells. Combination treatments with CDX and DTX at a lower (1nM)
concentration showed higher sensitivity than monotherapy (Figure 34A). Treatments with
AKTi at 0.5, 1.0 and 2.5µM concentrations reduced cell viability significantly for both cell
lines but to a much greater extent for cells expressing miR-17-92a (Figure 34B) compared
to control cells expressing Scr RNAs. Combination treatments with CDX (10uM)
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maintained the similar percentage of cell viability, which establishes a synergistic but not
an additive effect of both drugs (Figure 34B).
Next we examined the effect of miR-17-92a cluster on drug sensitivity of androgen
independent prostate cancer cells. Treatment of transiently transfected PC-3 cells
expressing miR-17-92a cluster miRNAs or Scr RNAs with DTX and Aurora kinase
inhibitor, VX680, in combination showed a significant reduction in cell viability but not
when treated singly, except at a higher concentration (25nM) of DTX (Figure 34D). We
tested a pan inhibitor of Aurora kinases as Aurora kinase inhibition, which causes mitotic
arrest and apoptosis, has been recognized as an effective anticancer therapeutic strategy
[137, 138]. Treatments with AKTi and DTX also showed a synergistic effect on reduced
viability of PC-3 cells upon expression of miR-17-92a cluster miRNAs compared to control
cells (Figure 34C) but not when treated singly. These observations indicate that restored
expression of miR-17-92a cluster has a potential therapeutic benefit for treatment of both
androgen dependent and CRPC cells.

102

Figure 34: Expression of miR-17-92a cluster miRNAs increased drug sensitivity of prostate
cancer cells.
Prostate cancer cells were transfected and treated with Casodex (CDX), docetaxel (DTX), pan-AKT inhibitor
MK-2206 2HCl (AKTi), or Aurora kinase inhibitor VX-680. Sensitivity to individual or combinational
treatments was measured through MTS assays. DMSO was used as the vehicle control. A and B. Androgen
sensitive LNCaP104-S cells were transiently transfected and treated for 48 hours A. Percent reduction in
viability of LNCaP cells expressing miR-17-92a miRNAs following treatment with 10 µM DHT, 10 µM CDX,
1 nM DTX, 5 nM DTX, and combination of 1 nM DTX + 10 µM CDX compared to cells expressing Scr RNAs.
Data represent mean±SD of 4 independent experiments. •p=0.00003; ••p=0.0008; *p=0.00001; **p=0.002;
***p=0.00003; ****p=0.00001. B. Percent reduction in viability of LNCaP104-S cells expressing miR-17-92a
miRNAs following treatment with 0.5 µM, 1 µM, and 2.5 µM AKTi alone or in combination with 10 µM CDX
compared to cells expressing Scr RNAs. Data represent mean±SD of 4 independent experiments. *p=0.01;
**p=0.004; ***p=0.008; •p=0.002; ••p=0.0006; •••p=0.0003. C and D. Androgen independent PC-3 cells
were transiently transfected and treated for 72 hours. C. Percent reduction in viability of PC-3 cells
expressing miR-17-92a miRNAs following treatment with 5 µM AKTi and 2 nM DTX or 5 nM DTX alone and
in combination. Results show a significant reduction in viability of PC-3 cells only during combination
treatments. Data show mean±SD of 3 independent experiments. *p=0.04; **p=0.03. D. Percent reduction
in viability of PC-3 cells expressing miR-17-92a miRNAs following treatment with 1 µM VX680, 5nM DTX
and 25 nM DTX alone or in combination. Data show a significant reduction in viability of transfected PC-3
cells upon 25 nM DTX alone and during combination treatment. Data represent mean±SD of 3 separate
experiments. *p=0.01; **p=0.02.

103

4.5 miRNA Expressions Deregulated in Human Prostate Tumors

4.5.1 Genome-Wide miRNA Expression Profiling in Clinical Specimens
Prostate cancer is the most frequently diagnosed cancer in American men, yet the
most commonly used biomarker for prostate cancer, PSA, is an unreliable prognostic tool.
There is a need to better differentiate indolent from aggressive prostate cancer in order
to properly treat this disease. The CAPRA-S scoring system was created to provide
predictive rates of recurrence following radical prostatectomy and is a more accurate
predictor of disease free regression compared to PSA values alone; however, an equally
accurate predictive tool to identify preoperative high risk from low risk patients is still in
need. To address this, we started investigating a possible correlation of CAPRA-S scores
with miRNA expressions.
We requested chart reviews for patients with prostate tissues available from the
Cooperative Human Tissue Network at UAB. CAPRA-S scores were calculated for each
patient and tissues were macro-dissected. We obtained samples for treatment naïve
patients stratified by risk grouping based on CAPRA-S score (low-risk 0-2, medium-risk
3-5, or high-risk ≥6). We used genome-wide miRNA array profiling approach to identify
miRNA expression profiles for each patient’s tumor and associated adjacent uninvolved
prostate tissue. Normalized relative expression values were generated using the qBase+
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software from Biogazelle.
Hierarchical clustering of the normalized and log2 transformed expression data
(Additional File 9) showed 4 distinct clusters of miRNAs (Figure 35 and Additional File
10). Clusters 1 and 3 identified miRNAs distinctly expressed between malignant and
uninvolved tissues (Figure 36A). The Log2 transformed relative expression values was
extracted from each cluster and the average expression of each miRNA was calculated
for both uninvolved tissue samples and tumor tissue samples. The average relative
expression for individual miRNAs(unidentified) in both uninvolved and tumor groups was
graphed (Figure 36B and C) for clusters 1 and 3 respectively. The dot plots display
distribution of average miRNA expression values for both groups including the average
of all miRNAs in the cluster (black bars) +/- 1 SD. In cluster 1 (Figure 36B) we identified
24 miRNAs (average values) that displayed down-regulation in tumor tissues compared
to uninvolved tissues. Examination of this cluster distinguished 6 miRNAs with on
average greater than 2 fold down-regulation in expression in malignant tissues. All 6
miRNAs (miR-133a/b, -143, -204, -221, -222) have published tumor suppressive
functions in prostate cancer and have been found to be down-regulated in PCa [139143]. Furthermore, miRs -143, -204, and -221/-222 are linked with CRPC or androgen
receptor function. Alternatively, the trend of average miRNA expression presented in
cluster 3 identified 17 miRNAs with increased expression in tumor tissues compared to
uninvolved tissues (Figure 36C). Cluster 3 also contained a subset of 6 miRNAs that
displayed on average a change in expression greater than 2 fold. However, these 6
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miRNAs (miR-375, -183, -93, -96, -127-5p, and -380) are expressed at higher levels in
malignant tissues compared to uninvolved tissue samples. All 6 miRNAs have been
found to be aberrantly expressed in cancer, while 5 of which (miRs -93/-375, -96, -183,
-380) have published oncogenic functions [144, 145],[146, 147]. The expressions of
miRNAs -93 and -375 are commonly overexpressed with miR-106b, another member of
cluster 3, and are believed to function in a regulatory axis promoting prostate cancer
progression [145].
Initial analysis of Cluster 2 and 4, identified from genome-wide expression analysis
(Figure 35), did not show the visibly unique expression patterns, between tumor and
uninvolved prostate tissues, previously identified in clusters 1 and 3. The cluster 2 heat
map (Figure 37A) depicts similar levels of expressions for all miRNAs (miR-103, -107, 29a/b/c, -199a/b-3p, and let-7a/b/d/e/g/i) within individual patient tissue; while, miRNAs
display heterogeneous expression across samples. Further interrogation of the cluster
revealed correlation of miRNA expression profiles with the patient’s CAPRA-S score.
Fifty percent (9/18) of tumor tissues from low and medium risk patients (CAPRA-S score
0-6) expressed cluster specific miRNA averages below the average observed in all
benign samples. However, 83% (5/6) of tumor tissues from high risk patients (CAPRAS score ≥ 7) expressed cluster specific miRNA averages below the average observed in
all benign samples. Dissecting the cluster into individual miRNAs, there was 2-fold
change in expression (+/- 0.2) for 9 of 13 miRNAs in cluster 2 while there was no
significant reduction observed in low and medium risk patient tumors (Figure 37C).
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These finding are in accordance with previous publications demonstrating tumor
suppressive functions for all cluster 2 miRNAs in prostate cancer [148-151]. In cluster 4,
the trend of increasing miRNA expression correlates positively with increasing risk of
disease recurrence, as predicted by CAPRA-S score groups: low risk (CAPRA-S 0-2),
medium risk (CAPRA-S 3-5) and high risk (CAPRA-S ≥6) (Figure 37B and D). Within
cluster 4, three miRNAs (miR-129-5p, -138, -519e) have been associated with resistance
to a Hsp90 inhibitor, Tanespimycin [152]. Hsp90 is known to promote AR activity [153],
and co-targeting of HSP90 in addition to androgen blockade is a proposed adjuvant
therapy [154]. Inhibiting Hsp90 when combined with AR antagonist, CDX, has shown to
suppress PCa growth and inhibit induction of AR-V7 a spice variant of AR known to be
involved in resistance to ADT [155]. Further investigation of this cluster of miRNAs may
provide a miRNA profile that could be used to identify the efficacy this combinational
therapy could provide on a patient specific basis.
The analysis of genome-wide miRNA expressions stratified by CAPRA-S score,
identified patterns of miRNA expression profiles consistent with our hypothesis and
previous reports. Emboldened by these results, we sought to identify miRNA expression
profiles differentially expressed in malignant prostate tissues of African American men,
specifically. The disparity in the rate of prostate cancer occurrence and mortality in
African American men, necessitates the identification of biomarkers specific for race and
ethnicity. From the data generated in our genome-wide profiling study, we compared the
relative expression of miRNAs in prostate tumor tissues from African American (AA) men
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against that of Caucasian American (CA) men. From this comparison we identified
miRNAs that, on average, exhibited ≥2-fold difference in expression (increase and
decrease), in African Americans compared to Caucasian Americans (Figure 38). The
miRNAs highlighted in Figure 38 (miR-541, miR-34c-5p, miR-135b, miR-299-3p, miR491-5p, and miR-30e) displayed reduced expression in the tumors of African American
men. The miRNAs also have been shown to negatively regulate the expression of AR in
prostate cancer cells [49]. Our data showing reduced expression of AR targeting miRNAs
in AA men indicate a possible up-regulation of expression of AR and, correlates with
previous studies showing increased expression of AR in the prostate tumors of AA men
relative to CA men [156, 157]. To better understand how these miRNAs are regulated
we examined the fold-change in expression of these miRNAs in patient specific tumor
tissues compared with matched benign prostate tissue. The patients were grouped by
race and subdivided by CAPRA-S score (0-3 or ≥4) (Figure 39). This analysis highlighted
the consistent pattern of down-regulation of these 6 miRNAs in AA men. In comparison,
CA patients displayed a much broader distribution in expression.
The genome-wide miRNA profiling has not been fully completed for all patients.
However, from the completed profiling, we have compared the fold change in expression
of miRNAs stratified by CAPRA-S risk groups and have identified the top 100 miRNAs
with the greatest FC in expression (50 up-, and 50 down-regulated) (Table 18 and Table
19)

108

Figure 35: Clustering of genome-wide miRNA expressions in tumor tissues and uninvolved prostate tissues
Hierarchal clustering of Log2 transformed relative expression values of miRNAs in uninvolved prostate and tumor tissues. Four clusters were
selected for further analysis.
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Figure 36: Analysis of clusters 1 and 3 identified from genome-wide miRNA profiling of prostate tissues
Hierarchal clustering of Log2 transformed relative expression values of miRNAs in uninvolved and malignant prostate tissues. A) Heat maps of
expression data for miRNAs in cluster 1 and 3; uninvolved tissue samples grouped under blue line (left side) and tumor samples grouped under
red line (right side). B and C) The average expression value of each miRNA was calculated for uninvolved tissue samples (blue circles) and
tumor samples (red squares). These values were used to generate dot plots for Cluster 1 (B) and Cluster 2 (C).
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Figure 37: Analysis of clusters 2 and 4 identified from genome-wide miRNA profiling of prostate tissues
Hierarchal clustering of Log2 transformed relative expression values of miRNAs in uninvolved and malignant prostate tissues. Correlation of
miRNA expressions with CAPRA-S risk group. A and B) Heat maps of expression data for miRNAs in cluster 2 (A) and 4 (B). A) Uninvolved
tissue samples grouped under blue line, low and medium risk patient tumor samples grouped under gold line, and high risk patient tumor samples
grouped under red line. B) Uninvolved tissue samples appear under blue line, low risk patient tumor samples grouped under purple line, and
medium grouped under orange line and high risk patient tumor samples grouped under red line. C and D) Average expression value of each
miRNA was calculated for uninvolved tissues and tumor tissues grouped by CAPRA-S risk. Values were used to generate dot plots for Cluster
2 (C) and Cluster 4 (D).
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Figure 38: Top miRNAs with differential regulation between Caucasian and African Americans
The relative expression of miRNAs in prostate cancer of African Americans was compared against that of Caucasian American men. The values
for induvial miRNAs that exhibited at least a 2-fold change were used to create the graph. A negative value represents decreased expression in
AA patient samples compared to CA samples. The identified miRNAs have been shown to regulate the expression of AR.
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Figure 39: Comparing expression of AR regulated miRNAs in African Americans vs Caucasians
The fold change in expression of AR regulating miRNAs grouped by race, African American (A) or
Caucasian American (C). Patients with CAPRA-S scores greater than 3 are identified by red symbols
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Table 17: Top 50 Down-Regulated miRNAs Across CAPRA-S Grouping
Low Risk
Fc

Med Risk Fc

HighRisk
Fc

Avg Fc

hsa-miR-204

-2.56

-1.83

-2.65

-2.28

hsa-miR-376c

-2.76

-2.04

-2.01

-2.25

hsa-miR-365

-2.05

-2.56

-2.05

-2.21

hsa-miR-221

-2.18

-2.07

-2.20

-2.14

hsa-miR-205

-1.21

-2.65

-4.26

-2.06

hsa-miR-133a

-2.52

-2.32

-1.36

-1.98

hsa-miR-143

-2.06

-1.97

-1.82

-1.95

hsa-miR-222

-1.90

-2.09

-1.63

-1.87

hsa-miR-218

-1.93

-2.19

-1.46

-1.85

hsa-miR-29a

-1.57

-1.93

-1.82

-1.81

hsa-miR-548b-5p

-1.27

-2.12

-2.22

-1.76

hsa-miR-452

-1.92

-1.87

-1.27

-1.73

hsa-miR-224

-1.16

-2.12

-2.69

-1.72

hsa-miR-29c

-1.42

-2.07

-1.64

-1.67

hsa-miR-125a-5p

-1.58

-1.82

-1.60

-1.67

hsa-miR-155

-1.68

-1.92

-1.39

-1.66

hsa-miR-24

-1.97

-1.41

-1.58

-1.62

hsa-let-7g

-1.54

-1.62

-1.74

-1.62

hsa-miR-424

-1.38

-2.20

-1.39

-1.61

hsa-miR-378

-2.24

-1.17

-1.82

-1.60

hsa-miR-517c

-2.38

1.02

-5.01

-1.60

hsa-miR-130a

-1.52

-1.82

-1.44

-1.59

hsa-miR-487b

-1.53

-1.54

-1.71

-1.59

hsa-miR-199a-3p

-1.65

-1.73

-1.37

-1.58

hsa-miR-211

-1.84

-1.73

-1.23

-1.58

hsa-let-7c

-1.51

-2.33

-1.22

-1.57

hsa-let-7a

-1.41

-1.61

-1.67

-1.55

hsa-miR-496

-1.09

-2.28

-1.59

-1.52

hsa-miR-99a

-1.42

-1.65

-1.50

-1.52

hsa-miR-196a

-2.09

-1.27

-1.39

-1.52

hsa-miR-125b

-1.61

-1.68

-1.26

-1.51

hsa-miR-100

-1.41

-1.66

-1.44

-1.50

hsa-miR-26a

-1.58

-1.67

-1.26

-1.50

miRNA
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Low Risk
Fc

Med Risk Fc

HighRisk
Fc

Avg Fc

hsa-miR-199b-3p

-1.50

-1.76

-1.25

-1.50

hsa-let-7b

-1.22

-1.73

-1.57

-1.47

hsa-miR-374b

-1.49

-2.08

-1.08

-1.46

hsa-let-7d

-1.34

-1.66

-1.42

-1.46

hsa-miR-299-5p

-1.81

1.02

-2.29

-1.46

hsa-miR-381

-1.52

-1.10

-2.14

-1.46

hsa-miR-142-5p

-1.53

-3.29

1.97

-1.45

hsa-let-7e

-1.44

-1.41

-1.44

-1.43

hsa-miR-193a-5p

-1.46

-1.69

-1.14

-1.42

hsa-miR-28-5p

-1.72

-1.44

-1.10

-1.40

hsa-miR-145

-1.77

-1.73

1.10

-1.38

hsa-miR-22

-1.45

-1.74

-1.06

-1.38

hsa-miR-193b

-1.33

-1.91

-1.06

-1.38

hsa-miR-181a

-1.79

-1.67

1.10

-1.38

hsa-miR-9

-1.15

-1.76

-1.33

-1.37

hsa-miR-338-3p

-1.42

-1.22

-1.61

-1.37

miRNA

-1.36
hsa-miR-379
-1.66
-1.55
1.06
Red Values > 2x fold change compared to adjacent uninvolved tissue.
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Table 18: Top 50 Up-Regulated miRNAs Across CAPRA-S Grouping
Low
Risk Fc

Med Risk
Fc

HighRisk
Fc

Avg Fc

hsa-miR-524-3p

1.03

2.54

2.86

2.08

hsa-miR-519a

0.59

1.50

5.99

2.30

hsa-miR-508-5p

1.88

1.21

4.48

2.32

hsa-miR-127-5p

2.38

2.61

1.92

2.35

hsa-miR-517b

1.77

2.24

3.24

2.36

hsa-miR-515-5p

3.30

2.47

0.43

2.39

hsa-miR-515-3p

1.13

3.89

2.08

2.40

hsa-miR-522

1.56

1.14

6.31

2.47

hsa-miR-146b-3p

1.89

3.05

2.22

2.49

hsa-miR-198

0.39

5.04

2.31

2.50

hsa-miR-96

1.72

2.50

3.71

2.51

hsa-miR-219-1-3p

1.12

3.26

3.55

2.54

hsa-miR-520e

1.70

1.05

5.85

2.59

hsa-miR-521

1.84

3.97

2.09

2.63

hsa-miR-34c-5p

0.93

2.01

5.79

2.65

hsa-miR-302c

0.72

3.44

4.54

2.72

hsa-miR-300

0.78

4.92

2.50

2.75

hsa-miR-330-5p

0.82

2.72

5.26

2.77

hsa-miR-501-5p

0.63

2.21

6.20

2.78

hsa-miR-183

1.93

1.89

4.95

2.81

hsa-miR-520c-5p

2.96

1.41

5.97

2.87

hsa-miR-182

1.74

1.88

5.55

2.88

hsa-miR-516b

2.67

1.47

5.78

2.88

hsa-miR-519e

1.26

1.91

6.62

2.89

hsa-miR-511

1.20

0.97

10.07

2.95

hsa-miR-545

3.08

2.27

4.61

3.02

hsa-miR-448

0.81

6.11

1.77

3.02

hsa-miR-512-5p

2.36

2.42

4.94

3.11

hsa-miR-506

1.27

3.71

4.73

3.12

hsa-miR-520d-5p

1.67

2.77

6.15

3.12

hsa-miR-517a

0.94

5.17

4.21

3.18

hsa-miR-519d

2.89

1.39

5.33

3.19

hsa-miR-301b

1.10

5.20

4.25

3.26

hsa-miR-544

4.45

3.20

1.24

3.30

hsa-miR-488

1.84

0.58

11.88

3.33

miRNA
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Low
Risk Fc

Med Risk
Fc

HighRisk
Fc

Avg Fc

hsa-miR-513a-5p

1.34

2.24

7.72

3.42

hsa-miR-206

6.57

1.16

1.83

3.51

hsa-miR-514

2.03

5.26

3.59

3.63

hsa-miR-299-3p

1.16

5.81

4.11

3.65

hsa-miR-302d

1.99

1.35

8.97

3.74

hsa-miR-525-3p

1.38

4.26

6.91

3.76

hsa-miR-548d-3p

2.97

4.80

2.98

3.77

hsa-miR-518d-3p

2.88

2.28

7.14

3.80

hsa-miR-380

3.10

5.97

1.67

3.86

hsa-miR-527

1.37

5.03

5.48

3.89

hsa-miR-507

4.10

3.15

6.26

3.99

hsa-miR-302e

3.03

4.85

6.43

4.23

hsa-miR-412

4.20

2.32

8.61

4.52

hsa-miR-103-as

1.12

7.49

9.17

5.57

miRNA

28.35
hsa-miR-371-3p
3.33
1.32
83.97
Red Values > 2x fold change compared to adjacent uninvolved tissue.
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CHAPTER FIVE: DISCUSSION
5.1 miRNAs Involved in the Transition to Androgen Independence

Our studies on profiling and validation of miRNA expressions during transition of
androgen-dependent LNCaP-104S cells to androgen-independent and CDX resistant
cells revealed activation and inactivation of several signaling networks. We noted a
difference in miRNA expressions between the androgen-independent subline LNCaP104R1, and freshly generated CDX resistant LNCaP-104S cells, which includes some of
the up-regulated (miR-146a) and down-regulated miRNAs (miR-15b-3p and miR-18b).
Although we noted differential expression of miRNAs between CS-FBS and CDX treated
LNCaP cells, we selected only miRNAs that showed either up-regulation or downregulation in all treated samples for analysis of their putative targets. Despite similar
expression profile of specific miRNAs in CS-FBS and CDX treated samples, some the
targets such as DOK4 and VEGF showed differential expression in CSFBS and CDX
treated cells. Presumably, this could be the effect of regulation of multiple targets by a
given miRNA, which may indirectly affect the net expression of DOK4 and VEGF.
Over expression of miR-146a was noted in all treated cells contrary to the study
showing loss of expression of miR-146a in CRPC [158]. Increased miR-146a expression
was substantiated by down-regulation of its two bona fide targets TRAF6 and IRAK1 in
both -104R1 and 3wks treated -104S cells. MiR-146a expression is induced by NF-κB
[159] and acts in a negative feedback loop through degradation of TRAF6 and IRAK1 to
118

reduce NF-κB signaling and inflammatory response. An increase in transcription of miR146a, as a result of elevated NF-κB activity is noted in thyroid cancer [160] and downregulation of miR-146a is associated with hyperactivation of NF-kB [161]. Despite this
association, an increase in NF-kB1 expression could be predicted in treated -104S cells,
as NF-kB1 is a direct target of the down-regulated miRNA miR-9 [162]. Increased
expression of the other subunit RelA, which heterodimerizes with NF-kB1 could also be
predicted as it is a direct target of the down-regulated miR-7 [163]. It appears that the NFkB signaling pathway is activated in the early stages of gaining resistance to
CDX/androgen blockade and the increased expression of miR-146a is a secondary effect
of the activation of the NFkB pathway. As a result, in the initial stages of anti-androgen
drug resistance there is decreased inflammatory response but down regulation of tumor
suppressor targets of miR-146a, BCORL1 [164] and RNASEL [165], which may not be
detected in fully developed CRPC. Furthermore, over-expression of miR-146a has been
identified in cells undergoing replicative senescence; which is a cellular fate induced by
androgen deprivation therapy and contributes to ADT resistance [166-168]. A recent
study has shown CDX treatment of LNCaP cells prevents AR from repressing expression
of CCAAT/Enhancer Binding Protein β (C/EBPβ), a transcription factor involved in
regulating proliferation and DNA damage response. Increased expression of C/EBPβ was
detected in CRPC, compared to naïve patients, and over-expression of C/EBPβ
sensitized LNCaP cells to cytotoxic chemotherapy following ADT [168]. Interestingly,
C/EBPβ mRNA is a predicted target of miR-17, miR-20a, miR-106a, miR-374a, and miR119

374b; all of these miRNAs were found to be down-regulated (or undetectable) upon CDX
treatment in our study. This suggests down-regulation of these miRNAs acts as a possible
survival mechanism for PCa cells undergoing ADT. To further support this hypothesis,
two studies published in May and June of this year (2016), linked down-regulation of a
miR-374a/b with acquired cisplatin resistance in pancreatic cancer cells and
nasopharyngeal carcinoma respectively [169, 170]. In nasopharyngeal carcinoma, miR374a decreased expression of CyclinD1 leading to reduced PI3K/AKT activity.
Additionally, miR-374a expression in nasopharyngeal carcinoma additionally reduced
expression of c-MYC, E2F1, Snail, N-cadherin [170]. These findings further parallel the
effect we observed in PCa cells over-expressing the miR-17-92a cluster.
The EGFR signaling pathway could also be activated in the early stages of
androgen blockade and CDX treatment. The evidence of EGFR pathway activation in the
treated LNCaP-104S cells is from our results showing an increased expression of EGFR,
down regulation of miR-7 and up-regulation miR-222, which are the miRNA regulators of
EGFR. Decreased expression of p27Kip1 and Cbl, as two other targets of the upregulated miR-222, further aid activation of EGFR signaling. C-Cbl, an E3 ubiquitin ligase,
inactivates ligand-bound EGFR through EGFR-Cbl complex formation leading to its
degradation [171]. C-Cbl activation mediates the tumor suppressive effects of EPhB6 and
inhibits cancer cell invasiveness [172]. C-Cbl is also targeted by the up regulated miRNA
miR-136 in all treated cells. Down regulation of c-Cbl in treated -104S and untreated 104R1 cells possibly promotes antiandrogen resistance through EGFR stabilization. A
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loss of expression of AR was noted in these cells, which supports the report showing an
inverse relationship between expression of AR and EGFR in prostate cancer patients
[28]. Up regulation of miR-136 in treated -104S cells was substantiated by the loss of
expression of the miR-136 target ZFAND1, an uncharacterized AN1 type zinc finger
domain 1 containing protein.
Activation of the PI3K/AKT signaling axis could also be predicted in treated -104S
cells, as a result of down regulation of miR-7, which inhibits tumor growth and metastasis
through inhibition of PI3K/AKT pathways [173]. Down-regulation of miR-7 in cancer cells
including glioblastoma and its inhibitory effects on EMT and metastasis is well
documented [174]. Activation of this pathway could be further aided by over expression
of miR-22 in all treated cells, which exerts a proto-oncogenic effect through downregulation of PTEN in androgen-independent prostate cancer cells [175]. Additionally,
activation of VEGF and DOK4 could be predicted, as these proteins are over expressed
in treated -104S cells possibly as a result of down-regulation of their regulatory miRNA,
miR-205. Earlier studies showed an association between poor prognosis of localized
prostate cancer and epigenetic repression of miR-205 [176], and thus confirms the
relevance of the loss of miR-205 in development of CDX resistance. DOK4 is a newly
identified substrate of ligand-bound insulin receptor (IRS-5), which, upon phosphorylation
translocates to mitochondria and recruits c-Src kinase to the mitochondria. Up regulation
of DOK4 is also noted in renal cell carcinoma [122]. VEGFA, also a target of miR-15b-5p,
showed 2-10-fold reduction in expression in treated -104S cells and in chemotherapy121

resistant squamous cell carcinoma [177].
Other than modulation of specific signaling axes, altered expression of miRNA
clusters is also evident in our study. Members of the miR-17-92a and its paralogous miR106a-363 clusters, miR-17, miR-18a, miR-18b, miR-20a and miR-106a showed ~9-10fold down regulation upon CDX treatment and androgen blockade. In support of our
observation, loss of expression of miR-17 [178], miR-18a [139], miR-20a [179] and miR106a [180] are reported in breast and other cancers. Loss of expression of miR-106a,
miR-17 and miR-20a are further supported by an increased expression of their target
protein FGD4 in these cells. Contrary to the published study [78], over-expression of miR34b was noted in AI and CDXR cells, however, an inverse relationship between miR-34b
expression and disease free survival of triple negative breast cancer has been reported
[181], which suggests that miR-34b expression may be dependent on the status of
hormone responsiveness. Among the other up-regulated miRNAs, over expression of let7f-1 [182], miR-143 [183], miR-218 [184], miR-29a [185], miR-302a [186], miR-3144
[187], miR-493 [188] and miR-664 [189] in cancer cells has been reported earlier. Our
study also identified a number of miRNAs with > 2-fold difference in expression such as
miR-3138, miR-3192, miR-3199, and a subset of miR-548 series, which are not yet known
to be involved in development of CRPC.
Additional miRNAs such as miR-518b, miR-205 and miR-596 showed a > 10-fold
loss of expression upon CDX treatment or androgen withdrawal. In support of our
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observation, loss of expression and tumor suppressor functions of mir-518b and miR-596
has been documented in other cancers [190]. MiR-1244 and miR-759 are two other
miRNAs that are significantly down regulated in all treated cells. This is substantiated by
an increased expression of their common target ABHD3 in these cells [112]. Among the
other down regulated miRNAs, miR-9 and miR-422a are known to have tumor suppressor
roles in various cancer cells [191, 192], whereas miRNAs -454, -3131 and -3185 are noted
for the first time to be deregulated during progression of CRPC.
Functional contribution of some of the identified microRNAs in development of
CRPC has been previously reported. Over expression of miR-222/221 in LAPC4 cells
was shown to promote androgen independent cell growth, which was abrogated upon
expression of anti-miR-222/221 inhibitors [58]. Down-regulation of miR-205 has been
correlated with advanced prostate cancer and ectopic expression of miR-205 suppressed
AR and MAPK signaling and inhibited cell growth [193]. Down-regulation of miR-17 in AI
prostate cancer cells has also been demonstrated. Expression of pre-miR-17 in these
cells prevented AR-induced gene transcription and inhibited cell proliferation [50].
Analysis of the altered cellular processes during progression towards CDX
resistance and androgen independence showed a decreased percentage of miRNAs
involved in cancer but an increased percentage in reproductive system, endocrine
system, hepatic system and metabolic diseases. It can be speculated that up-regulated
oncomiRs at earlier stages aid in transformation of cells through suppression of tumor
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suppressors. Whereas, at later stages accumulation of abnormal cellular events triggers
expression of additional sets of miRNA, which inhibit key regulatory proteins involved in
metabolic process, hormone response and other cellular events. Our qRT-PCR FC data
indicate differential expression of miRNAs between 1wk and 3wks treatment, which would
have been undetected had the profiling been done only in CDX sensitive/AD and –
resistant/AI cells. In silico analysis identified a number of targets that are potentially
regulated by one or more altered miRNAs. This includes, two mitosis regulatory proteins
CCNJ and CHAMP1 (ZNF828) [114, 115]; two oncogenic proteins PIK3CD [194] and
MYB that are over expressed in CRPC [116]; a protein trafficking regulatory protein
,RAB9B; a ubiquitination promoting protein, SPOPL, involved in the Hedgehog/Gli
signaling pathway [117]; and E2F1, transcription factor [121].
The overall evaluation of the changes in expression profiles of miRNAs during
transition of CDX-sensitive and AD cells to the CDX-resistant and AI ones demonstrates
that not any one or two miRNAs are responsible for development of drug-resistant
prostate cancer. Instead, a complex network of activation and inactivation of specific
signaling pathways, aided by degradation or accumulation of the target mRNAs as a
result of differential expression of a significant number of miRNAs, plays the pivotal role.
Also, there are transient changes in the expression of miRNAs as well as their target
proteins during transition of cells towards ADT resistance, which may provide growth and
survival advantage to a subset of cancer cells; and these changes in miRNA/mRNA
signature may be missed in already developed castration resistant prostate cancer.
124

5.2 Functional Significance of miR-17-92a Expression in Prostate Cancer

In our analysis of miRNAs associated with androgen independence we identified
the miR-17-92a cluster which displayed loss of expression as cells developed resistance
to ADT and CDX. This suggests a possible tumor suppressive role of these miRNAs;
however, this observation is contradictory to the published studies showing increased
expression of miR-17-92a cluster miRNAs in lung cancer [195] and B-cell lymphomas
[196]. The change in expression may either be driven by occasional amplification of the
13q31.3 locus and/or hyperactivation of Myc oncogene in these tumors, which is a potent
transcriptional activator of MIR17HG gene, leading to increased synthesis of the primary
transcripts of these miRNAs [197]. Alternatively, it may be due to increased stabilization
of the mature miRNAs by endogenous regulatory RNAs or proteins that may lead to
accumulation of these miRNAs. The expression pattern of miR-17-92a in prostate tumors
also corroborated with the expression levels in prostate cancer cell lines, which further
confirms the loss of expression of miR-17-92a cluster in prostate cancer. In support of
our observations, down-regulation of miR-17-5p and miR-17-3p in prostate cancer cell
lines and tissues have been documented earlier [50, 198].
Our studies on the functional consequence of the restored expression of miR-1792a cluster miRNAs in PC-3 prostate cancer cells revealed down-regulation of RhoGTPase signaling pathway proteins FGD4 and LIMK1, and cell cycle regulatory proteins
cyclin D1 and SSH1, which have predicted binding sites of miRs-17 and -20a at the 3’
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UTRs. Our study established FGD4 as a direct target of miR-17, and -20a, which is also
overexpressed in prostate tumors with higher Gleason scores and in androgen
independent tumors (unpublished observation in our laboratory). Importantly, the role of
FGD4 in promotion of cancer cell migration has also been reported [124]. Although all six
miRNAs were expressed from a single vector, the levels of expression of individual
miRNAs varied with a maximum expression of miR-17 and -20a in both PC-3 and M12
cells (Figure 26). This result suggests that expression of the miR-17-92a cluster facilitates
establishing an anti-oncogenic environment in prostate cancer cells, as overexpression
and oncogenic/metastatic functions of LIMK1, cyclin D1 and SSH1 have been
documented in prostate and other cancers [199-201]. The functional identity of miR-1792a cluster in prostate cancer cells is further supported by our results showing reduced
activation of ERK1/2 kinases and AKT in these cells. Reduced proliferation of these cells
as noted by Ki67 staining and cell proliferation assays also aids in the overall
interpretation of our results.
Results showing antitumorigenic and tumor growth inhibitory effects of miR-17-92a
cluster further strengthen the inference that the miR-17-92a cluster exhibits tumor
suppressor effects when expressed in highly aggressive tumorigenic prostate cancer
cells. This effect could be mediated by differential regulation of cell cycle promoting cyclin
D1 expression. The miR-17-92a cluster also inhibits expression of CDK inhibitor p21 gene
[202], which inhibits G1/S transition, but inhibition of cyclin D1 expression by the miR-1792a cluster could be more robust in these cells showing a net anti-proliferative effect of
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these miRNAs. Furthermore, miR-17-92a cluster miRNAs also target E2F1 [203], which
may be destabilized and further contribute to retardation of cell proliferation. Our study
also demonstrates a migration inhibitory function of miR-17-92a cluster, which is
substantiated by increased expression of e-cadherin and reduced expression of other
mesenchymal markers. Migration inhibitory effects of miR-17-3p expression have been
reported earlier in prostate cancer cells, which showed reduced vimentin expression upon
of miR-17-3p overexpression [198].
Importantly, our studies further establish the potential of the miR-17-92a cluster as
a therapeutic target, showing improved sensitivity of androgen-dependent and independent prostate cancer cells to some of the drugs that are currently being used for
the treatment of CRPC, such as anti-microtubule (DTX), AKTi, anti-androgen (CDX)
(androgen dependent cells) and anti-Aurora kinases (androgen independent cells). It can
be speculated that the enhanced sensitivity of the miR-17-92a cluster expressing
LNCaP104-S (androgen sensitive) cell line to CDX is mediated through interfering
androgen receptor function, as miR-17-5p has been noted to inhibit androgen receptor
transcriptional activity through targeting p300/CBP [50]. The improved sensitivity of
androgen independent PC-3 cells expressing miR-17-92a cluster to DTX and VX680 in
combination is presumably mediated through the inhibition of LIMK1 expression and
activity (Figure 27and Figure 28), as LIMK1 destabilizes microtubules [204] and interferes
with DTX induced microtubule stability, and active LIMK1 is needed for Aurora kinase A
functional activation [205]. The enhanced sensitivity to AKTi, singly and in combination
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with CDX (LNCaP104-S) or DTX (PC-3) of both cell types expressing the miR-17-92a
cluster, is also through miR-17-92a expression-associated inhibition of AKT activation
(Figure 28).
Anti-proliferative, adhesive and anti-migratory properties of miR-17 upon
overexpression in non-tumor cells and overall growth retardation and smaller organs in
transgenic mice has been reported earlier [206] but our results show the maintenance of
similar distinctive functions of the expressed miR-17 in the presence of expression of the
other miRNAs of the cluster in prostate cancer cells. It is possible that both miR-17 and 20a, which share the exact seed sequence but slightly different central region, are
maximally expressed in the transfected cells and in tumors and may functionally
synergize. It is now becoming increasingly clear that altered expression of specific targets
decides the fate of a cell and the functional designation of a miRNA. Because of the
intricacies of the complex regulatory network and fine-tuning of gene expression by
miRNAs and competing endogenous regulatory RNAs (ceRNAs), caution should be
exercised to understand the function of miRNAs within the cellular context. Taken
together, our results strongly support the designation of miR-17-92a cluster miRNAs as
tumor suppressors for prostate cancer and that replenishment of expression of miR-1792a miRNAs as a cluster could be used for combination therapy with other frontline
chemotherapeutic agents for treating tumors with a potential for biochemical failure.
Nonetheless, the reason for loss of expression of miR-17-92a cluster miRNAs in prostate
tumor is not clear, which could be a result of transcription silencing through hyper128

methylation of the CPG Islands or enhanced destabilization of mature miRNAs. In depth
studies are required to understand the mechanistic roles of miR-17-92a cluster in
modulation of particular pathways that lead to inhibition of cell proliferation and increased
drug sensitivity.

5.3 MicroRNAs as Potential Biomarkers in Prostate Cancer

Looking beyond the miR-17-92a cluster, we examined the miRNA landscape in
prostate tumors from patients with varying CAPRA-S scores in an effort to identify
distinguishing features. Our analysis identified groups of miRNAs that exhibited similar
patterns of expression that differentiated tumor from benign tissues or varied with respect
to CAPRA-S risk group. Furthermore, many of the miRNAs we identified as differentially
expressed in prostate cancer are supported by similar findings published by other
investigators. Our initial findings are promising and identify miRNAs with novel
association with known oncomiRs or tumor suppressive miRNAs. More patient tissues
need to be screened for validation of expression before we can firmly identify miRNA
profiles that are predictive of a patient’s risk of disease recurrence or resistance to certain
chemotherapeutic strategies.
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APPENDIX: DESCRIPTION OF ADDITIONAL FILES
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Additional File 1: List of normalized and log-transformed values of the miRNA expression.
Additional File 2: List of the p-values, expression patterns and IDs of significant miRNAs
identified in t-tests.
Additional File 3: List of the log-transformed fold change values of the up regulated and
down regulated miRNAs identified in miRNA profiling.
Additional File 4: List of miRNAs in specific clusters identified in K-median cluster
analysis.
Additional File 5: List of the p-values, expression profile and IDs of significant miRNAs
from the list of validated miRNAs identified in two samples t-tests.
Additional File 6: List of the log-transformed values of the fold change in expression of
the validated miRNAs.
Additional File 7: List of the up and down regulated subset of the validated miRNAs in
specific clusters identified in K-median cluster analysis.
Additional File 8: Expression of total- and phospo- AKT1, ERK1/2, and PRAS40 in PC-3
cells expressing Scr RNA or miR-17-92a
Additional File 9: List of normalized expression values of miRNAs, in prostate tumor tissue
samples and adjacent uninvolved prostate tissue samples, used for hierarchal clustering
analysis.
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Additional File 10: List of log-transformed relative expression values and averages of
miRNAs identified in clusters 1, 2, 3, and 4.

Source of Additional Files 1-7:
Ottman, R., C. Nguyen, R. Lorch & R. Chakrabarti (2014) MicroRNA expressions
associated with progression of prostate cancer cells to antiandrogen therapy resistance.
Mol Cancer, 13, 1.
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